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ABSTRACT
Introduction To realise the expected gains from 
prevention of mother- to- child HIV transmission initiatives, 
adherence to preventative and therapeutic antiretroviral 
regimens is critical and interventions deployable in 
busy programmatic settings with a high HIV burden are 
needed. Based on formative research, we developed an 
approach that integrates patient- centred counselling 
and engagement of an adherence supporter for pregnant 
and breastfeeding women initiating HIV treatment (ie, 
antiretroviral therapy (ART)) or biomedical HIV prevention 
(ie, pre- exposure prophylaxis (PrEP)).
Methods Tonse Pamodzi 2 is a pilot study designed 
to provide acceptability, fidelity and clinical outcomes 
data on a set of behavioural interventions for adherence 
support. The study comprises two parallel randomised 
trials, enrolling HIV- positive pregnant women initiating 
ART (Trial 1, n=100) and HIV- negative pregnant women 
with risk of HIV acquisition and willing to initiate PrEP 
(Trial 2, n=200). Within each trial, participants are 
randomised 1:1 to either the intervention or control group. 
The Tonse Pamodzi adherence intervention comprises 
patient- centred counselling (adapted Integrated Next Step 
Counseling(iNSC)) and external adherence support tailored 
to the clinical context (ie, for ART or PrEP). Participants 
randomly assigned to the control group receive standard 
counselling based on local HIV guidelines. Participants are 
followed for 6 months. To assess intervention acceptability, 
we will employ a mixed method approach to describe 
participant engagement, satisfaction, and discussion 
content. We will audit and score recorded counselling 
sessions to evaluate the implementation fidelity of iNSC 
sessions. We will also assess clinical outcomes at 3 
and 6 months for both Trial 1 (retention in care and viral 
suppression of HIV) and Trial 2 (retention in care, and 
plasma and intracellular tenofovir drug concentrations).
Ethics and dissemination The study protocol was 
approved by the Malawi National Health Science Research 
Committee (19/05/2334) and the University of North 
Carolina at Chapel Hill Institutional Review Board (19-
1060).
Trial registration number NCT04330989.
INTRODUCTION
Over the past two decades, services for 
prevention of mother- to- child transmission 
(PMTCT) of HIV have expanded rapidly in 
sub- Saharan Africa, resulting in dramatic 
reductions in paediatric HIV.1–3 The progres-
sion of scientific, programmatic and policy 
advances have led to calls to eliminate mother- 
to- child transmission of HIV (EMTCT).4–6 To 
achieve these ambitious benchmarks, ‘status- 
neutral’ approaches that offer universal 
services regardless of maternal HIV status 
are urgently needed.7 Such an approach can 
Strengths and limitations of this study
 ► We designed a status- neutral adherence interven-
tion for pregnant and breastfeeding women that can 
be tailored to support adherence to either antiret-
roviral therapy for HIV- positive women or HIV pre- 
exposure prophylaxis for HIV- negative women at 
elevated risk of acquiring HIV.
 ► Our study is designed to evaluate the interven-
tion’s acceptability, fidelity and associated clinical 
outcomes.
 ► Study limitations include a relatively short follow- up 
period (ie, 6 months) and a targeted patient popu-
lation; however, these features are consistent with 
other feasibility studies.
 ► Results from these pilot trials will inform the design 
of a larger study to assess the efficacy of the Tonse 
Pamodzi adherence intervention.
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increase acceptability and reduce the stigma associated 
with HIV treatment and prevention services for pregnant 
and breastfeeding women.
In most African settings, PMTCT programmes have 
focused on the diagnosis, treatment, and retention of 
HIV- positive women within antenatal settings. The WHO 
and country- level policies support the provision of life-
long antiretroviral therapy (ART) for all HIV- positive 
pregnant and breastfeeding women (ie, the Option B+ 
strategy), which may reduce HIV transmission rates to 
less than 2%.8–11 Nevertheless, challenges remain. ART 
uptake among pregnant and breastfeeding women 
is not universal and nearly 20% of women drop out of 
care in the first 6 months on treatment.9–14 Further, poor 
adherence to ART can lead to antiretroviral drug resis-
tance, treatment failure, and horizontal and vertical 
transmission.15–18
Incident maternal HIV infections—acquired during 
pregnancy and breast feeding—further contribute to the 
paediatric HIV burden,18 with up to 45% of new paedi-
atric HIV cases attributable to new maternal HIV infec-
tion during pregnancy and breastfeeding in countries like 
Malawi.19 In 2018, the Joint United Nations Programme 
on HIV/AIDS estimated as many as 130 000 women 
acquired HIV during pregnancy and breastfeeding,1 
consistent with the high HIV incidence observed in clin-
ical studies.20 21 For most pregnant women who initially 
test HIV negative, few HIV prevention services are avail-
able, presenting a missed opportunity as these women are 
already engaged in care. Oral pre- exposure prophylaxis 
(PrEP) is recommended by the WHO to reduce hori-
zontal HIV transmission and is considered safe and effec-
tive during pregnancy.22–24 Although the acceptability 
and feasibility of PrEP in antenatal/postnatal settings are 
encouraging,25–27 challenges to sustain uptake and adher-
ence persist due to low risk of perception, perceived 
stigma and concerns about medication side effects.28
To reach the ambitious goals of EMTCT, effective 
and yet scalable approaches are needed to enhance 
current HIV services, including combination strate-
gies that integrate proven biomedical and behavioural 
interventions. Given the critical role of medication 
adherence for both HIV treatment (ie, ART) and 
prevention (ie, PrEP), approaches that are adaptable 
and capable of being tailored to support antiretro-
viral use regardless of the context in which they are 
prescribed—treatment or prevention—may offer 
particular benefits in busy clinical settings. Such status- 
neutral interventions could broaden HIV services 
in maternal and child health settings. We developed 
an intervention combining patient- centred counsel-
ling (Integrated Next Step Counseling (iNSC)) and 
the inclusion of a participant- identified adherence 
supporter to enhance antiretroviral drug use during 
pregnancy and breastfeeding. In this protocol paper, 
we describe a pilot study to obtain data about the inter-
vention’s acceptability, fidelity and clinical outcomes.
METHODS AND ANALYSIS
Study overview
Tonse Pamodzi 2 (TP2) is a pair of pilot studies designed to 
evaluate an adherence support intervention for ART and 
PrEP. The term tonse pamodzi means ‘all of us together’ in 
Chichewa and Nyanja, signifying the importance of inte-
grated facility- based and community- based adherence 
support. TP2 comprises two parallel randomised trials, 
evaluating an adapted integrated adherence support 
strategy for a different antenatal population. Trial 1 is 
enrolling HIV- positive pregnant women who have initi-
ated ART; Trial 2 is enrolling HIV- negative pregnant 
women who meet local eligibility criteria to start PrEP 
(figure 1). The study enrolment began in March 2020 
for Trial 1 and in June 2020 for Trial 2. The protocol is 
Figure 1 Consolidated Standards of Reporting Trials flow diagram. IDI, in- depth interviews; iNSC, Integrated Next Step 
Counseling.
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registered in  ClinicalTrials. gov. Online supplemental 
appendix 1 gives as a summary of the trial registration 
details.
Study site
The Bwaila District Hospital is a district level public 
hospital serving approximately one million people in 
Lilongwe and surrounding rural villages. It is the busiest 
maternity hospital in Malawi, with approximately 150 
pregnant women attending antenatal care every day and 
over 1200 deliveries every month. Bwaila District Hospital 
has been providing PMTCT services since April 2002. 
Similar to many parts of Lilongwe, the antenatal HIV 
prevalence is estimated as 12%.29
Adherence support: intervention group
The TP adherence intervention was developed following 
intensive formative research—including systematic 
reviews;21 30 qualitative interviews with patients, health-
care workers and policymakers;26 31 and mathematical 
modeling32—and expert consultation. It comprises two 
parts: an adaptation of iNSC and the optional inclusion of 
an adherence supporter who is from the patient’s social 
network. Figure 2 provides an overview of the interven-
tion session activities; a detailed description is included in 
online supplemental appendices 2 and 3.
A core component of our adherence support inter-
vention is iNSC, a patient- centred counselling approach 
that adopts a systematic process or flow of conversation 
to promote patient engagement and autonomy as coun-
sellors guide the conversation towards the identification 
of needs related to health and well- being, sexual health 
protection, and/or adherence (table 1).
iNSC has been used in several studies and programmes 
to support adherence for PrEP in different populations, 
but has never been tested among pregnant women.24 33 34 
The goal of iNSC is to foster a collaborative problem- 
solving environment that allows the participant to iden-
tify their individual needs to create, enhance or sustain 
overall well- being, sexual health through non- biomedical 
approaches, and adherence to antiretroviral drugs. iNSC 
frames the counselling sessions as a non- judgmental 
discussion to explore one’s current experiences; one’s 
vision for an alternative experience that would make 
health promotion easier/easiest to manage; and the facil-
itators, challenges and needs for progressing towards that 
improved situation. Although the content of these discus-
sions is entirely tailored to the specific participants’ situ-
ation, clinical context and priorities, the process of the 
conversation is identical across participants. Participants 
in the intervention arm receive iNSC at study enrolment 
and their visit at months 1, 3 and 6.
All individuals receiving the intervention are also 
invited to identify an adherence supporter or Omukhu-
lupilira (‘close confidant’ in Chichewa and Nyanja) from 
their own social network. As part of the approach, this 
individual is trained to support the participant’s use of 
ART or PrEP and may accompany the participant to 
study visits. The Omukhulupilira may be a partner, family 
member or friend chosen by the participant who can 
provide emotional, instrumental and informational social 
support. Selecting an Omukhulupilira is recommended, 
but not mandatory. Once nominated, an Omukhulupilira 
receives a brief in- person orientation training on how to 
provide positive support to the participant. This includes 
Figure 2 Overview of the Tonse Pamodzi 2 adherence intervention.
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basic HIV knowledge, the importance of antiretroviral 
adherence, potential drug side effects, and practical 
strategies for supporting adherence. This intervention 
component is based on the premise that social support 
provides access to essential information and resources to 
encourage specific health behaviours.35
Adherence support: current standard of care
Participants randomly assigned to the control group 
receive standard counselling in PMTCT, safe obstet-
rics and newborn care, based on the Malawi Ministry of 
Health guidelines.36 In addition, all participants receive 
education regarding HIV/AIDS—including HIV treat-
ment and prevention—when they initiate either ART or 
PrEP. The content of this education comprises the basics 
of HIV transmission and prevention, stages of HIV infec-
tion, the role of ART or PrEP for PMTCT and their mech-
anisms of action, dosing and adherence guidance, and 
drug safety and side effects.
Recruitment and retention procedures
Participants are recruited from the antenatal clinic at 
Bwaila District Hospital in Lilongwe, Malawi. Study staff 
provide educational talks about the study in the antenatal 
waiting areas. Pregnant women interested in the study are 
booked for screening at the research clinic and undergo 
informed consent before study procedures begin. Once 
participants are enrolled in the trial, the study team uses 
a multipronged strategy—including telephone contact, 
community outreach and peer engagement—to retain 
those in both arms to minimise losses to follow- up. The 
study team closely monitors retention and addresses any 
issues prospectively.
Randomisation
Participants are randomised separately within each trial 
and the randomisation procedures are similar between 
the two parallel studies. Within each trial, participants are 
randomly assigned 1:1 to either the intervention or control 
arm using a permuted block randomisation design.37 
The study statistician (KRM) independently generated 
the randomisation assignments using SAS V.9.4 software. 
Opaque, sealed randomisation envelopes for Trial 1 and 
Trial 2 were numbered in advance of enrolment by an 
independent data staff member and stored in sequential 
order in separate boxes. Team members preparing these 
envelopes are not involved in ascertaining eligibility or 
assessing outcomes. Once eligibility is confirmed and the 
participant provides informed consent (online supple-
mental appendix 4), the research nurse obtains the next 
sequential envelope from the box for the randomisa-
tion assignment, enters the randomisation identification 
number on the envelope into the participant’s linkages 
form and then opens the envelope to determine rando-
misation assignment. Due to the nature of the interven-
tion and data collection instruments, it is not possible 
to blind clinic staff, study statisticians or participants on 
the assigned randomisation arm. However, the labora-
tory technicians responsible for measuring biological 
endpoints are blinded to the randomisation assignment.
Considerations for Trial 1 (ART adherence support)
Eligibility criteria for Trial 1: We are enrolling HIV- 
positive women 18 years of age or older with documented 
pregnancy by urine pregnancy test or physical examina-
tion. Other eligibility criteria include initiation on first- 
line ART within the past 30 days, for the first time or after 
treatment interruption of 6 months or longer (if previ-
ously started, but stopped ART). HIV- positive women 
initiating ART may be enrolled on the same day if they 
meet the eligibility criteria. The women should be willing 
to provide written informed consent, remain in the study 
site’s catchment area throughout study follow- up, and 
comply with the visit schedule. Women with risk for inti-
mate partner violence (IPV) or social harms resulting 
from participation as assessed by study personnel are 
excluded.
Table 1 Steps and content for Integrated Next Step Counseling
Step Content
Introduce Explain what you want to discuss, why and ask permission
Frame discussion Frame discussion to two components, first about general well- being and then about adherence. Steps 
below will be repeated for each component.
Review Check in on previous goals/discussions, close and move into current experiences (follow- up visits only)
Explore Discuss socioecological factors that challenge or could optimise a specific behaviour
Tailor Reflect on context and experiences shared to tailor remainder of the discussion
Identify Ask what would be needed to happen for the situation (identified above) to be slightly better, easier to 
handle or be more manageable
Strategise* Ask how the participant might consider addressing this need
Agree* Ask the participant if she would agree to try out one or more strategies to address the identified need
Transition/close* Move to a new topic and repeat the flow or close the discussion
*These steps may be repeated in a joint discussion with the adherence supporter (ie, Omukhulupilira), if he/she is present and the participant 
agrees.
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Study activities for Trial 1: Visits occur at enrolment, 
and at months 1, 3 and 6 (table 2). The study procedures 
at these scheduled visits include collecting blood and 
urine specimens for the following laboratory tests: HIV 
RNA (viral load), haemoglobin, syphilis screening (if 
not available in the antenatal record) and urine dipstick 
(table 2). These specimens are collected for safety moni-
toring and outcome measurement. Urine dipstick is 
collected per local standard of care. HIV viral load is 
measured onsite using the HIV RNA PCR on M2000 plat-
form (Abbott Laboratories, Lake Forest, Illinois, USA) at 
the University of North Carolina Project Malawi Central 
Laboratory (Lilongwe, Malawi). Most index pregnancies 
are expected to end prior to the participant’s 6- month 
study visit, and we collect obstetric and neonatal infor-
mation when the pregnancy outcome is available. In 
the event that the index pregnancy is ongoing at the 
participant’s 6- month study visit, we schedule additional 
monthly follow- up visits until the participant can report 
an obstetrical outcome. ART regimens are prescribed 
according to local HIV guidelines:36 tenofovir disoproxil 
fumarate (TDF) and lamivudine with either dolute-
gravir or efavirenz. The dispensation of ART is coordi-
nated with the local PMTCT/ART programme at the 
study facility. We collect information about prescribed 
ART drugs, pharmacy dispensations and adherence eval-
uations at short visits every month, timed with routine 
clinic visits.





Enrolment Month 1 Month 3 Month 6 Monthly
Laboratory studies
  HIV RNA (viral load) X   X X   
  Haemoglobin X         
  Syphilis screening X*         
  Urine dipstick X   X X   
Medical examination
  Medical history X         
  Obstetric examination X X X X   
Questionnaires
  Social and demographic information X         
  Pregnancy history X   X X   
  Sexual partners X   X X   
  Social harms X X X X X
  Intimate partner violence X   X X   
  Substance abuse X     X   
  HIV status disclosure X X X X   
  COVID-19 questionnaire X X X X X
  LifeWindows—ART adherence46 X   X X   
  Multidimensional Scale of Perceived Social Support X   X X   
  Pregnancy and delivery status   X X X X
  ART adherence questionnaire   X X X X
Drug dispensation and adherence assessment
  Participant- specific dispensing record X X X X   
Intervention assessment (intervention arm only)
  Overall intervention acceptability   X X X   
  Integrated Next Step Counseling acceptability   X X X   
  Adherence supporter acceptability   X X X   
  Qualitative interviews (subset) X†   X† X†   
*Will perform test if no results available in the medical record.
†Schedule additional procedures within 30 days of visit for subset of participants enrolled in this component.
ART, antiretroviral therapy.
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Considerations for Trial 2 (PreP adherence support)
Eligibility criteria for enrolment in Trial 2: In Trial 2, 
we enrol HIV- negative pregnant women 18 years of age 
or older willing to initiate and continue daily oral PrEP, 
coformulated as TDF and emtricitabine (TDF/FTC; 
200/300 mg). To be eligible, candidates must report one 
or more of the following risk factors for HIV acquisition in 
the past 12 months: known positive or unknown partner 
HIV status, multiple sexual partners, diagnosis of a sexu-
ally transmitted infection, use of postexposure prophy-
laxis, use of shared injection material or equipment, or an 
unspecified concern about HIV acquisition. Other eligi-
bility criteria include documented pregnancy by urine 
pregnancy test or physical examination, a documented 
negative HIV status within the past 3 months, plans to 
remain in the study site’s catchment area throughout 
study follow- up, willingness to provide informed consent 
and comply with the visit schedule, and interest in initi-
ating and continuing PrEP throughout study follow- up. 
We exclude women who test positive for hepatitis B 
surface antigen at the time of screening, have renal insuf-
ficiency (defined as creatinine clearance <90 mL/min), 
have a history of known renal parenchymal disease or have 
a known single kidney at the time of screening. Women 
with risk for IPV or social harms resulting from participa-
tion as assessed by study personnel, are excluded.
Activities for Trial 2: In Trial 2, participants undergo 
screening procedures to confirm their HIV and hepatitis 
B status, both of which must be negative before enrol-
ment and randomisation. Study visits will occur at enrol-
ment and at months 1, 3 and 6 (table 3). We use oral 
PrEP coformulated as TDF/FTC, to be dosed on a once- 
daily basis. The packaged product is dispensed for Trial 
2 participants by onsite study staff. Participants begin 
daily administration of TDF/FTC on the day of rando-
misation and this will continue through month 6. PrEP is 
dispensed for 1–3 months at a time, depending on local 
control measures for COVID-19 (see COVID-19 consider-
ations below). Study laboratory tests at baseline include 
rapid HIV antibody screening, alanine transaminase, 
creatinine, syphilis screening (if not available in the ante-
natal record) and urine dipstick. At follow- up visits, tests 
include HIV antibody screening, urine dipstick, creati-
nine, tenofovir (TFV) concentrations, and intracellular 
TFV- diphosphate (TFVdp) measurements. These speci-
mens are collected both for routine safety monitoring for 
PrEP and as outcome measurements. As in Trial 1, if the 
index pregnancy is ongoing at the 6- month study visit, 
we will schedule monthly follow- up visits until the partic-
ipant reports a pregnancy outcome. Specimens for TFV 
concentration and TFVdp measurements are stored at 
the local site laboratory and then shipped for processing 
at the University of North Carolina at Chapel Hill by the 
Clinical Pharmacology and Analytical Chemistry Core of 
the Center for AIDS Research.
For women who test HIV positive during the study, 
TDF/FTC will be discontinued while the diagnosis is 
confirmed. We will also collect a specimen for HIV RNA 
(ie, viral load) and storage for HIV resistance testing. If 
the HIV diagnosis is confirmed, the participant completes 
exit study procedures (ie, analogous to the 6- month visit) 
and receives a guided referral to the HIV care and treat-
ment clinic at the study site.
Acceptability and fidelity endpoints
Mixed methods assessment of intervention acceptability: 
Among those randomised to the intervention group, we 
assess the acceptability of the integrated intervention and 
its component parts (ie, adherence supporter and iNSC) 
at each study visit. This includes questions about overall 
satisfaction and, if the intervention were to be made avail-
able again, likelihood of continued use. We inquire about 
aspects of the iNSC experience, including the discussion 
content, counsellor engagement and perceived effect 
on adherence behaviours. We also ask about whether 
they are working with an Omukhulupilira and, if so, 
his/her level of engagement in adherence support and 
perceived effect on adherence behaviours. Questions are 
structured with binary outcomes (eg, yes/no) or using 
a five- point Likert scale. To complement these quanti-
tative assessments, individual semi- structured interviews 
(SSIs) are conducted to further explore participant expe-
riences with the TP intervention. We are interested in 
individual- level engagement (including satisfaction with 
the different components), as well as barriers and facili-
tators to participation. With three interviews planned (ie, 
following enrolment, and at 3- month and 6- month visits), 
our approach provides a longitudinal assessment of the 
intervention. We are recruiting a subset of 40 study partic-
ipants, all from the intervention group, divided equally 
between the two trials.
Quantitative assessment of iNSC fidelity: We conduct 
detailed audits of iNSC sessions for all participants 
assigned to the intervention arm from both trials (n=150 
total). A case report form is used to document fidelity to 
each component of the iNSC session. Two reviewers inde-
pendently rate the iNSC session according to key domains, 
providing both objective and subjective measures about 
the quality of the counselling. Through this process, our 
audit staff also assess the appropriateness of documenta-
tion in the primary case report forms, including misinfor-
mation and missing data. This exercise provides critical 
feedback loops to improve counselling over time.
Clinical endpoints
In addition, we collect longitudinal participant outcomes 
data at 3 and 6 months for both trials. In Trial 1 (HIV- 
positive women), we will examine an endpoint of reten-
tion in care with viral suppression of HIV (<40 copies/
mL). In Trial 2 (HIV- negative women), we will examine 
retention in care with adherence to PrEP as measured 
by plasma and intracellular TFV drug concentrations at 
6 months following study enrolment. Using published 
algorithms,38 results from the plasma and upper layer of 
packed cells assays are combined to develop a composite 
adherence score (table 4). Our Trial 2 clinical outcome is 
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Enrolment Month 1 Month 3 Month 6 Monthly
(if rapid HIV test 
is positive)
Laboratory studies
  Rapid HIV antibody test X X   X X     
  Hepatitis B antigen X         
  Alanine aminotransferase   X       
  Creatinine X   X X     
  Syphilis screening     X *       
  Urine dipstick   X X X X     
  Tenofovir concentration       X X     
  HIV RNA (viral load)         X
  Storage for HIV resistance 
testing
        X
Medical examination
  Medical history X       
  Obstetric examination X X X X X     
Questionnaires
  Social and demographic 
information
  X       
  Pregnancy history   X   X X     
  Sexual partners   X   X X     
  COVID-19 questionnaire   X X X X X   
  Social harms   X X X X X   
  Intimate partner violence   X   X X     
  Substance abuse   X X     
  Motivating factors for PrEP 
use
  X       
  Perceived HIV risk 
assessment
  X   X     
  PrEP use disclosure   X X X X     
  LifeWindows—PrEP 
adherence46
  X   X X     
  Multidimensional Scale of 
Perceived Social Support
  X   X     
  PrEP adherence 
questionnaire
    X X X X   
  Pregnancy and delivery 
status
    X X X X   
Drug dispensation and adherence assessment
  Participant- specific 
dispensing record
  X X X X X   
Intervention assessment (intervention arm only)
  Overall intervention 
acceptability
    X X X     
  Integrated Next Step 
Counseling acceptability
    X X X     
Continued
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based on functional adherence, defined as 4–5 or more 
doses/week (scores of 4 or 5).
In line with pilot designs, our study is not formally 
powered to detect clinically meaningful differences 
between study arms (see the Sample size section). Instead, 
these data will be used to assess the feasibility of future 
trials, including in the areas of recruitment and reten-
tion. These preliminary endpoint data will also provide 
baseline estimates for future studies, especially for PrEP 
use among pregnant and breastfeeding women, where 
adherence data remain scarce.
Safety monitoring
At each study visit, the study staff will evaluate participants 
for social harms, IPV and AEs (Adverse Events). We will 
use standardised instruments to screen for social harms 
and IPV. Social harms involve problems with other people 
as a result of study participation. IPV involves physical or 
sexual violence experienced with a partner. An AE will be 
defined as any untoward medical occurrence in a study 
participant, including an abnormal physical examina-
tion or laboratory finding, symptom or disease, tempo-
rally associated with the individual’s participation in the 
research, whether or not considered related to partic-
ipation in the research. The severity of events will be 
graded using the National Institute of Health’s Division 
of AIDS Table for Grading the Severity of Adult and Pedi-
atric Adverse Events. Participant deaths will be recorded 
along with the contributing cause(s) of death. We will 
also record information on all serious adverse events 
occurring in participants, whether or not they are related 
to study participation or the study drug. Because our 
combination intervention is designed to enhance adher-
ence—and because the Malawi Ministry of Health already 
recommends the prescribed antiretroviral regimens—a 
data monitoring committee has not been convened.
Sample size
In Trial 1, we plan to enrol 100 HIV- positive pregnant 
women, randomised 1:1 between the intervention and 
control arms (n=50 each). In Trial 2, we plan to enrol 200 
HIV- negative pregnant women, randomised 1:1 between 
the intervention and control arms (n=100 each). Similar 
to other pilot studies, these sample sizes were selected 
based on practical considerations, including recruitment 
ability, participant flow, and budgetary constraints. We 
enrolled larger number of HIV- negative women in Trial 2 
because assessments of PrEP adherence during pregnancy 
and breastfeeding are limited in the medical literature. 
These sample sizes were deemed sufficient to evaluate the 
acceptability and fidelity endpoints described above. We 
also conducted exploratory precision and power calcula-
tions for our clinical endpoints over a range of potentially 
meaningful effect sizes.
Data management
Clinical and behavioural data collected during this study 







Enrolment Month 1 Month 3 Month 6 Monthly
(if rapid HIV test 
is positive)
  Adherence supporter 
acceptability
    X X X     
  Qualitative interviews   X†   X† X†     
*Will perform test if no results are available in the medical record.
†Schedule additional procedures within 30 days of visit for subset of participants enrolled in this component.
PrEP, pre- exposure prophylaxis.
Table 3 Continued
Table 4 Adherence composite scores based on TFV and TFVdp concentrations, with doses estimated/interval
Score TFV in plasma TFVdp in ULPC Estimates doses per interval
0 None detectable <10 000 fmol/mL Low number or no doses in the interval
1 Detectable <10 000 fmol/mL A few doses in the entire interval
2 Any level 10 000–100 000 fmol/mL 1–2 doses/week
3 <10 ng/mL >100 000 fmol/mL Several doses early in the interval, followed by a stop in the 
1–2 weeks leading up to sampling visit
4 10 ng/mL or higher 100 000–1 000 000 fmol/mL 4–5 doses/week
5 10 ng/mL or higher >1 000 000 fmol/mL Approximately daily dosing
Adapted from Corneli et al.38
TFV, tenofovir; TFVdp, tenofovir diphosphate; ULPC, upper layer packed cells.
copyright.











pen: first published as 10.1136/bm




9Saidi F, et al. BMJ Open 2021;11:e046032. doi:10.1136/bmjopen-2020-046032
Open access
software.39 Access to study data is restricted to a limited 
number of team members (data coordinator, study 
coordinator and study investigator). For the qualitative 
interviews, the SSI audio recordings are transcribed and 
translated for analysis. All identifiers are redacted from 
the interview transcripts before analysis. Weekly data 
monitoring reports, including the performance indica-
tors, are generated to monitor study progress. Deidenti-
fied data will be made available via existing online data 
repositories once the planned analyses are completed and 
data sharing agreements are established with proposed 
investigators and institutions.
Confidentiality
Measures are being taken to ensure the safety of data and 
confidentiality of all our study participants. All participants 
are assigned a unique coded study identification numbers 
(ID) number. The interview guides will not capture names 
of the participants, but only coded study ID. No partici-
pants will be identified in any report or publication about 
this study. Clinical information with individual identifiers 
will not be released without the written permission of the 
participant. We expect these procedures to protect partic-
ipant confidentiality adequately.
Data analysis
In our assessment of intervention acceptability, we will 
tabulate participant responses about engagement, satis-
faction and discussion content. Only participants in the 
intervention group will be included in these analyses and 
the results will be stratified by trial. Outcomes will be 
reported as a proportion, with precision quantified using 
95% CIs. We will examine the responses to our five- point 
Likert scale and, depending on their distribution, report 
them as either categorical or binary variables. To comple-
ment these qualitative data, we will analyse SSI data to 
gain additional insights about intervention acceptability. 
Data will be analysed using established techniques that 
include coding, memoing and matrices to summarise 
and interpret key patterns in the data. Comparative and 
thematic analyses will be used to provide an in- depth 
understanding of the experiences related to HIV testing.
To assess fidelity, each iNSC session will be scored 
(range 0–100) and then stratified by individual partic-
ipant, type of study visit, staff member providing iNSC 
and calendar time. This will allow us to describe trends in 
fidelity over the course of participant follow- up time and 
calendar time. We will describe scores overall and by steps 
within iNSC.
Analyses of clinical endpoints will be conducted sepa-
rately for each trial. Given the nature of these pilot studies, 
emphasis will be placed on estimation and precision. In 
Trial 1, we will assess ART adherence by evaluating the 
viral suppression status of each study participant at 3 
and 6 months after randomisation. Participants not lost 
to follow- up will be classified as either virally suppressed 
(<40 copies/mL) or not virally suppressed (≥40 copies/
mL). The proportion of women retained in care with viral 
suppression will be compared between randomisation 
arms by estimating the risk difference and corresponding 
95% CI. In Trial 2, we will assess PrEP adherence by eval-
uating retention in care and functional PrEP use for 
each study participant at 3 and 6 months. Mirroring our 
approach in Trial 1, the proportion of women retained in 
care with functional PrEP use will be compared between 
randomisation arms using a risk difference and corre-
sponding 95% CI. Women who do not attend the month 
6 visit will be counted as failures and contribute to the 
analysis denominator.
The incidence of social harms, IPV and other AEs will be 
estimated by randomisation arm and, where possible, by 
individual event types. Study retention will be described 
for each scheduled visit using frequency tables, and 
reasons for attrition will be described. Adherence to ART 
and PrEP will also be measured both by self- report and 
pharmacy measures. A medication possession ratio will be 
estimated and described using summary statistics, using 
established thresholds to dichotomise this endpoint.40 41 
We will compare these composite adherence outcomes 
between randomisation arms using a risk difference and 
corresponding 95% CI.
Patient and public involvement
Prior to commencing recruitment, the local Commu-
nity Advisory Board (CAB) was engaged to review the 
study aims and recruitment procedures. The CAB 
consists of local community and religious leaders, 
community representatives and adolescents repre-
senting the youth. CAB meetings were held bimonthly 
to review progress in enrolment and retention, and 
to solicit feedback about ongoing successes and chal-
lenges with study implementation.
COVID-19 considerations
Due to the ongoing COVID-19 pandemic,42 we have 
modified our activities to increase the safety of staff 
and participants. All study personnel practice personal 
safety measures when interacting with others, including 
personal protective equipment, frequent handwashing 
and physical distancing.43 All participants wear face 
masks when being attended to on the study site. To mini-
mise the number of clinic visits, we dispense study drugs 
(either ART or PrEP) for longer durations—aligned with 
study activities—and conduct monthly adherence assess-
ments via phone. All directives from the Malawi Ministry 
of Health are followed and an information sheet is used 
to provide participants with up- to- date information on 
COVID-19 preventive measures.
Ethics and dissemination
The study protocol has been reviewed and approved by 
the Malawi National Health Science Research Committee 
(19/05/2334) and the University of North Carolina at 
Chapel Hill Institutional Review Board (19-1060). Any 
protocol modifications are submitted to and approved by 
these committees before any change in implementation. 
copyright.











pen: first published as 10.1136/bm




10 Saidi F, et al. BMJ Open 2021;11:e046032. doi:10.1136/bmjopen-2020-046032
Open access 
Study findings will be disseminated through appropriate 
local channels, including academic and public health 
research symposia.
DISCUSSION
The TP2 study comprises two parallel trials to support 
antiretroviral adherence in the setting of antenatal and 
postnatal care, both for ART (Trial 1) and PrEP (Trial 
2). This pilot study will provide important data on inter-
vention acceptability, fidelity and clinical outcomes. Our 
overarching goal is to assess these attributes, while evalu-
ating the feasibility of the TP2 adherence intervention for 
future efficacy trials.
Our trial focuses on two different pregnant and 
breastfeeding populations that may benefit from 
adherence interventions—HIV- positive women on ART 
and HIV- negative women on PrEP. For the HIV- positive 
group, we focused on those who had recently initiated 
HIV treatment or restarted following a prolonged (ie, 
greater than 6 months) interruption. We reasoned that 
the timing of our combination behavioural interven-
tion may be most relevant during this start/restart 
window. However, we also recognise the importance of 
adherence support for those on long- term ART, even 
in shorter periods. If shown to be acceptable in our 
pilot study, we would look to expand the eligibility 
criteria in follow- on studies.
Similar to other settings in sub- Saharan Africa, the 
provision of PrEP during pregnancy and breastfeeding in 
Malawi remains limited. This study will provide important 
acceptability data about PrEP use, including self- reported 
and objective measures of adherence. Although we 
considered common challenges to PrEP delivery in 
the design of our study, some barriers were difficult to 
address. For example, the integration of PrEP dispensa-
tion with routine antenatal/postnatal visits may promote 
adherence and persistence.27 44 However, such evaluation 
schedules did not align with our adherence assessments 
or our relatively short (ie, 6 month) follow- up period. 
Nevertheless, as part of our acceptability assessments, 
we will gather data that can inform future PrEP delivery 
strategies.
While we expect to gain insights into antiretroviral 
adherence during pregnancy and breastfeeding, the 
design of this pilot study emphasises the former period. 
All participants are enrolled during pregnancy, with the 
expectation that most will deliver prior to the 6 months 
and continue in follow- up. The vast majority of new 
mothers in Malawi opt to breastfeed their children45 
and, as such, we did not make the intention to breast-
feed a separate eligibility criterion for the trial. Our 
assessments of acceptability and fidelity will consider a 
women’s pregnancy status (ie, antenatal or postnatal) 
and allow us to evaluate the intervention across these 
related, but distinctly different time periods. The study 
will also provide some descriptive data about PrEP safety 
in pregnancy and breastfeeding, both for the participant 
and her newborn.
In summary, the TP2 study evaluates a new combi-
nation intervention to support antiretroviral adher-
ence. This pilot study will provide important data about 
the intervention’s acceptability, fidelity and clinical 
outcomes promoting consistent ART and PrEP use. 
Once completed, our study will provide insight into 
broad strategies for HIV prevention and treatment that 
are status neutral, and able to support both HIV- positive 
and HIV- negative pregnant women in sub- Saharan 
Africa.
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If the anticipated gains for the biomedical prevention of mother-to-child HIV transmission (PMTCT) programs 
are to be realized, adherence to antiretroviral regimens for both treatment and prevention of HIV are critical.  
Adherence can be defined as the extent to which a patient follows a treatment plan, takes prescribed 
medicines as directed, and follows any related restrictions regarding food and other medications. There are 
other important factors that go into successful outcomes—like coming in for recommended care or medication 
refills (retention in care), the length of time someone is committed to a given treatment (persistence), or a mix 
of all of these (patient engagement).  
Over the years, different models and frameworks for how and why people may struggle with adherence 
particularly have been developed and so have different approaches to trying to optimize outcomes for 
antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP). Humans are ultimately social creatures, so it 
is not surprising that partner, friend, and/or family support can be very valuable for women and improve 
adherence and retention in antenatal and HIV programs. Adherence support from team members trained in 
patient-centered, person-facing counselling and communication can also help individuals to optimize 
medication adherence.  
This workbook describes an intervention that is a combination approach to improve adherence for women 
initiating antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) during pregnancy. It has been 
designed for the Tonse Pamodzi 2 study (TP-2). This combination intervention includes Integrated Next Step 
Counselling (iNSC) and an adherence supporter model (Omukhulupilira) that helps pregnant and breastfeeding 
women to develop their own strategies to improve adherence in the context of their overall well-being.  
Women receiving this combination intervention will have dedicated time with a specialized counselor at their 
enrollment, Month 1, Month 3 and Month 6 study visits. In addition, they will be given the opportunity to identify 
an omukhulupilira (“close confidant” in Chichewa and Nyanja), an individual who will be educated and trained 
to support the participant’s use of ART or PrEP, and may accompany the participant to study visits. Over the 
course of the four study visits, study counselors will provide iNSC and—if a support person is identified—
support omukhulupilira interactions, in ways that encourage adherence to antiretroviral medications in the 
context of general well-being. This is described in greater detail in this manual. 
 
INTERVENTION COMPONENTS 
1. Integrated Next Step Counselling (iNSC) 
iNSC is a two-phase discussion opened with an invitation to explore experiences and intentionally framed as a 
process rather than a series or set of messages. Although steps are articulated to guide implementers through 
the iNSC process, the driving goal is to engage participants in a non-judgmental discussion of their 
experiences surrounding protection of sexual health. iNSC is a process for having a conversation. It draws 
from the Information, Motivation, Behavioral Skills model situated within a socio-ecological context. The iNSC 
discussion assumes that the participant is the expert of their own experiences, that experiences are influenced 
by multiple factors, that there are diverse pathways to adherence and engagement in sexual health, that these 
pathways can be identified through exploration, and that facilitated exploration can lead to clients identifying 
their own needs and strategies. iNSC training emphasizes the importance of engaging in a genuine, as 
opposed to formulaic or predetermined, conversation framing the discussion around the specific context and 
needs of the participant. Communication is intentionally neutral (non-judgmental), avoids telling participants 
what they must or should do, and draws on strengths, resources, and facilitators.  
 
2. Adherence supporter model (Omukhulupilira)  
A recommended but optional component of the intervention, the omukhulupilira, will be a person chosen by 
each participant who can provide emotional, instrumental, and informational social support to help the 
participant adhere to their ART/PrEP regimen. In Chichewa and Nyanja, “omukhulupilira” means a close 
confidant. If and once selected by the participant, the omukhulupilira will receive a brief in-person training on 
how to provide positive support to the participant during a structured orientation visit. At the participant’s 
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invitation, they will have the opportunity to join portions of the iNSC sessions after they have completed the 
orientation visit. In these sessions, the counselor and participant may call on the omukhulupilira to help discuss 
barriers to adherence, strategies to overcome these barriers, and their role in helping the participant to 
implement these strategies as appropriate. The role of the omukhulupilira outside of these sessions will be 
determined by this discussion and the needs and preferences of the participant. 
 
OVERVIEW OF INTERVENTION SESSIONS 
 




I. Welcome & education debrief 
II. iNSC 
• Health in context: sexual health (PrEP) or 
general well-being (ART) 
• PrEP/ART adherence 
III. Exploration & selection of omukhulupilira 
IV. Close session 
N/A not yet selected 
Omukhulupilira 
orientation 
(As early as 
possible, but not 
restricted) 
Encouraged to attend, but not mandatory 
I. Education about HIV and PrEP/ART 
II. Social support for adherence 
III. Coaching to provide support 
IV. Closing the session & next steps 
Adherence check-in     
(Month 1 and    
Month 3) 
I. iNSC session 
• Health in context: sexual health (PrEP) or 
general well-being (ART) 
• PrEP/ART adherence  
 
If the omukhulupilira is present, determine 
whether the participant would like to discuss 
further in a joint session 
If present, participate in discussion of selected 
adherence strategies and potential role to 




I. iNSC session 
• Health in context: sexual health (PrEP) or 
general well-being (ART) 
• PrEP/ART adherence  
• Discussion of future steps, including links 
to the standard of care 
 
If the omukhulupilira is present, determine 
whether the participant would like to discuss 
further in a joint session  
If present, participate in discussion of selected 
adherence strategies and potential role to 




All counselors must have completed training on procedures and received confirmation from the supervisory 
team that he/she is ready to implement the intervention. Additionally, counselors should not only be facile with 
the intervention approach (iNSC) but should also have had the opportunity to gain knowledge and feel 
confident in any of the education material that the participant will have received prior to the iNSC session (in 
case there are questions and to identify potential misinformation). Finally, awareness of crisis counseling 
techniques for those working with newly diagnosed pregnant women is required. Ongoing supervision and 
training are provided throughout the study by the supervisory team.     
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NOTES ABOUT THIS MANUAL 
An important goal of this intervention is to learn from the participant and tailor counseling messages in their 
individual context. As such, it is critical that the conversation flows freely and is directed to the participant’s own 
experiences, needs, and obstacles. In this manual, we include sample text in blue italicized font. These 
examples are meant as guides only and should not be recited verbatim.   
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After consent and enrollment, participants will be randomized to intervention or standard of care. ALL 
participants will have engaged in [ART/PrEP] education before meeting with the intervention counselor, as 
required by the study protocol. As such, participants may feel tired, overwhelmed or otherwise distracted by the 
time she meets with the intervention counselor. We will deliberately include comfort check-ins and efforts to 
promote participant engagement in intervention conversations. Welcoming participants and providing an 
overview of the session, while checking in on their current state of mind, is essential to this and must be 
attempted before getting into exploration of sensitive topics like sex and health. This is particularly critical for 
women who only recently learned of their HIV status. 
 
SESSION COMPONENTS 
Participants assigned to the intervention condition will go from receiving the standard education information 
about [ART/PrEP] and clinic visits to meeting with trained intervention counselors. During this part of the visit, 
participants will be asked to engage in the following 4 general phases of interaction: 
 
1. Welcome and education debrief  
2. iNSC  
3. Exploration and selection of omukhulupilira  
4. Close session with plan for next steps 
 
1. WELCOME AND OVERVIEW 
The enrollment session begins with an overview of the intervention package.  
 
Introducing yourself, the intervention and this session 
My name is __________. Thank you for meeting with me today! Thank you joining the study. You have 
been selected to take part in the study intervention, which will help you with [ART/PrEP]. I will be 
checking with you each time you come to clinic to see how things are going. For this first conversation 
together, I am hoping to spend some time getting to know you better, share information with you and 
explore your thoughts, feelings and plans for your journey with [ART/PrEP].  
Check in on comfort 
Before we begin, I want to check in with you. You have been here a while today [and for newly 
diagnosed “and no doubt this has been challenging”]. We will spend about 30-45 minutes talking 
together today. Before we begin, do you need to use the rest room or take a break? Can I get you a 
snack or beverage? [list whatever amenities you have at the site] 
Explain the program and your role 
This program works with people starting [ART/PrEP] with the goal of helping people to feel confident 
and motivated to follow their regimen to the best of their ability. Moreover, it gives people the space to 
talk frankly about their experiences, even when those experiences may involve challenges- like missing 
doses or just not feeling like taking doses. Our conversations are about your needs, and we do not 
share this information with your medical care providers. It is private. The only thing I cannot keep 
private are situations where you may be in danger. If that is the case, then you and I will work together 
with other members of the care team here to ensure your safety. Sound OK? 
Thank you. Each time you come in for [ART/PrEP], I will be checking with you to see how things are 
going. For this first conversation together, I am hoping to spend some time getting to know you better, 
share information with you and explore your thoughts, feelings and plans for your journey with 
[ART/PrEP].  
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Ask permission to carry on 
Does that sound OK to you? Do you have any questions before we begin? 
 
Education debrief – before moving further, check in on information the participant received already today 
You have received a lot of information from the clinic staff today. What did you find most meaningful in 
all that was shared?  
[Reflect] 
Are there any pieces of information you heard that were not so clear or seemed hard to understand or 
believe? 
[Process] 
Any time you have questions about the information you receive, please let me or other members of the 
study staff know. We can help to clarify or explain further. The more informed people are, the better! 
 
2. iNSC 
The iNSC component of the session includes two parts.  
The first part is a broader discussion about general well-being. This initial phase provides some information 
about the situational context for adherence behaviors and helps to build rapport with the participant. For 
individuals on ART, the emphasis is on general well-being; for individuals on PrEP, the focus is on sexual 
health.  
The second part focuses in on use of [ART/PrEP], including challenges and facilitators of adherence. This is a 
direct discussion about how to achieve and maintain medication adherence. 
All intervention counselors will be trained in the conduct of iNSC, using the iNSC Workbook (see Appendix). 
The iNSC discussion structure is shown in the table below. This follows with usual steps of iNSC, with the 
exception of the Review step, which may be skipped in first sessions because there are no previous goals or 




Introduce Explain what you want to discuss, why, and ask permission 
Frame 
discussion 
Frame discussion to two components, first about general well-being and then about adherence. 
Steps below will be repeated for each component. 
Review Check in on previous goals/discussions, close and move into current experiences (follow-up visits 
only) 
Explore Discuss socio-ecological factors that challenge or could optimize a specific behavior 
Tailor Reflect on context and experiences shared to tailor remainder of the discussion 
Identify Ask what would be needed to happen for the behavior (identified above) to be easier to handle or 
be more manageable  
Strategize  Ask how the participant might consider addressing this need 




Move to a new topic and repeat the flow OR close the discussion  
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3. EXPLORATION AND SELECTION OF OMUKHULUPILIRA OPTION 
The intervention counselor introduces the role of the omukhulupilira and how he/she may help to support 
ART/PrEP adherence. Below is an example of how this discussion may start. 
Part of this program is to talk together when you come in for your [ART/PrEP]. Another service that we 
offer involves what we call an omukhulupilira, someone outside of the clinic who supports you and 
helps you to take [ART/PrEP]. Being able to take a medication every day can be hard. Many people 
find it helpful to have a family member or friend that they can rely on to help them remember to take 
their medicine, attend medical appointments, keep their spirits up, or just be there to talk about things. 
Research suggests that people who have someone important to them help out with adherence and 
their efforts to [treat/prevent] HIV may have better chances of being able to do so. 
For this study, we recommend that participants select an omukhulupilira. This may be a partner, family 
member, or friend who can support your adherence both during and outside of study counseling visits. 
Their exact role will be determined by your preferences and needs. You also do not have to select an 
omukhulupilira if you do not want to. You can select someone today, or at any other study visit. 
If you desire, your omukhulupilira can attend study counseling sessions with you. If you wish, your 
omukhulupilira can join us at the end of the counseling session to discuss ways to support your 
adherence. Outside of the counseling sessions, she/he can help you to implement these adherence 
strategies and may be a helping hand or someone to lean on for emotional support. The exact support 
they provide will depend on your needs, but some things that are often helpful include: 
• Helping you remember to take your medication 
• Helping you get to the clinic or refill prescriptions 
• Providing encouragement or emotional support 
• Providing child care so you can attend clinic appointments 
Some people have important others in their lives that they want to involve in their efforts to use 
[ART/PrEP] as recommended. We also know that not everyone has or wants that. If you do have 
someone you could see being your supporter, we are able to work them into parts of our sessions so 
that your plans, goals or strategies can be supported by that person.  
Just knowing what you know right now, and how you feel right now, what is your reaction to/thoughts 
about an omukhulupilira? 
 
If the participant is uninterested in identifying an omukhulupilira, thank her and ask for permission to revisit this 
topic at the next session and skip to Part 4 (Close the Session) below.  
Thank you. I understand that an omukhulupilira is not for everyone. When you think about it, what are 
the main reasons you do not want that right now? Thank you. I respect your careful consideration on 
this. I will check in with you at your next visit about this service—and periodically throughout the 
study—just in case something changes. Is this okay? 
 
If the participant is interested in selecting an omukhulupilira (or exploring further), cover the remaining sections 
below as appropriate.  
Material Needed: the Omukhulupilira Orientation Visit Invitation Card, the Omukhulupilira Agreement Form. 
 
 
A. Important considerations when selecting an omukhulupilira  
As we’ve discussed, the support that you will receive from the omukhulupilira will depend upon your 
needs, your relationship with them, and their capacity to provide support. It will be slightly different for 
each person. There are few things to consider when deciding on the appropriate supporter for you: 
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1) In most cases, it will be helpful if the omukhulupilira is someone you can see regularly outside of 
the counseling sessions so they can provide the support that you agree upon together. 
2) If you have not done so already, you will need to disclose your [if applicable: HIV status] and 
[ART/PrEP] use to the person you select as your omukhulupilira (if you choose one). 
3) Once you have selected an omukhulupilira, we will ask them to come in for an orientation 
session so that we can coach them on how to support you outside of study counseling sessions. 
Your [if applicable: HIV status] and [ART/PrEP] use will be discussed during this orientation 
session. 
4) Omukhulupilira may come with you to our clinic counseling sessions, but this is entirely up to 
you. If they come, they can join us after the counseling session to discuss how they can support 
your adherence. 
Is there someone you can think of—a friend or family member you trust, [if applicable: who knows 
your HIV status], and who you see often—who might be appropriate and willing to be your 
omukhulupilira?  
Allow person time to think and respond.  
If not ready, let participant know that you can check in again next time they come in or they can simply 
bring the person with them to the next visit. Then go to Part 4 (Close the Session).  
If the participant remains interested, continue to the next section. 
 
B. Explore possible candidates 
Work with the participant to reflect on the possible advantages and disadvantages of approaching 
potential people for this role. Gauge their interest and comfort in approaching each possible candidate.  
• Are you currently staying with [candidate’s name]? 
• Do you feel comfortable informing [candidate’s name] that you have started [ART/PrEP]? What will 
you tell them? 
• Can you ask [candidate’s name] to come in for an orientation visit? What words might you use? 
• Do you see any problem(s) having [candidate’s name] come here for the next visit? If yes, how so? 
• Would you like [candidate’s name] to join us after the counseling sessions to talk about how they 
can support your adherence? 
Allow participant to continue exploring advantages and disadvantages—and different considerations—
for each of the potential omukhulupilira candidates. When the conversation feels ready to move 
forward, continue to the next section. 
  
C. Nominating an omukhulupilira 
Ask the participant if she feels ready to identify an omukhulupilira. If no, remind participant you will 
check in again or if she does identify someone between visits, she can just let you know or bring in the 
person to her next visit. Then move to Part 4 (Close the Session).   
For participants who are ready to nominate an omukhulupilira, review and complete the Omukhulupilira 
Nomination Form with them and ask them to sign and date the form. If the participant is unable to sign 
their name, ask them to provide a fingerprint instead. Read the form aloud to the participant and help 
them to complete and sign the form 
On this form we will record identification information about the omukhulupilira you named, and any 
alternate individuals who might participate if that person is not available. This information will help us to 
make sure that we have the right person in the case that you are not able to come to the Orientation 
Visit. We also want to make sure that you understand what will be discussed with the omukhulupilira if 
they attend this visit. 
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D. Scheduling a visit with the omukhulupilira 
If the participant is able to attend the visit, find a day and time for the visit that works for them, and 
complete the invitation card accordingly, otherwise simply provide the card. Instruct them to provide the 
card to the person they have determined is able to serve as their omukhulupilira. If they have 
nominated multiple potential omukhulupilira, ask them how they will determine which person to provide 
the invitation card to. Thank the participant before transitioning to closing the visit. 
Now that you’ve selected a potential omukhulupilira, he/she will need to come in to this clinic for an 
orientation visit to learn how to work with you and the counselor to support your use of [ART/PrEP]. 
While not mandatory, we encourage you to take part in this orientation visit along with the 
omukhulupilira. Do you think you will be able to attend the visit with your omukhulupilira? 
 
4. CLOSE THE SESSION WITH PLAN FOR NEXT STEPS 
Provide a summary of what was discussed, thank the participant and remind her of the next visit. 
We have covered a lot today. Thank you for sharing with me. Before you go, I just want to summarize 
some important parts of our conversation. OK? You mentioned that you need ___________ to feel 
[well, motivated to protect yourself, committed to your health and wellbeing, to feel using condoms 
works, so on] and ___________ would be a strategy you would be willing to try out to help with that. 
And for [ART/PrEP], you need ___________ and you are going to try [strategy] to see if that can be 
addressed.   
You also [identified/decided against] selecting an omukhulupilira at this time. [If applicable] We will 
schedule a time to meet with this individual, as previously described.  
Thank you for talking with me. I look forward to asking you about how things went. It is OK to give 
something a try and feel it is not quite right. Something that sounds perfect here may feel not so perfect 
once you leave this space and get into your daily life. If that happens, keep trying. Keep thinking of 
ways you might work with [repeat needs] just like we did here together.  Thank you! 
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Visit Date: Completed by: 
 
 
PrEP/ART Status (as of today’s visit Support Discussion  
□ on or getting PrEP → Full iNSC 
□ on or getting ART→ Full iNSC 
 
Sexual Health Promotion/Wellbeing Counseling – iNSC  
1 INTRODUCE / FRAME: Introduction to session provided? □ yes □ no 
2 REVIEW: The participant’s experiences/goals reviewed □ yes □ no  □ NA (first visit, no goals from last visit)   
3 EXPLORE: Experiences with sexual health protection through behavioral strategies. What strategies are used/considered? What promotes those 
(makes it easy)? What challenges use of protection strategies (makes it hard)? 
Facilitators (said by participant) Challenges (said by participant) 
□being well informed 
□partner(s) supports strategies  
□personal commitment (motivation) to staying HIV negative 
□confidence in negotiating strategies with sexual partner(s) 
□having intimacy (closeness) with partner 
□fits well into what I do sexually 
□feeling “at risk” 
□none could be identified 
□other, specify: 
 
□not feeling well informed 
□partner(s) unwilling/reluctant/against to practice strategies 
□ fearful of rejection or missed opportunity (ruining the mood) 
□specific incentives to not use strategies (pay or trade) 
□not thinking that getting HIV would be bad 
□thinking partners are HIV-negative without really knowing their status 
□feeling down/sad (not caring about protecting self) 
□interferes with intimacy 
□drug or alcohol use (making decision making difficult)  
□caught up in the moment 
□none could be identified 
□other, specify:  
 
 
4 TAILOR: Level of engagement in this part of counseling:   □low  □medium  □high 
5 IDENTIFY or confirm needs:  Needs (What would make using protection strategies or sustaining ones that work “easier”? Select all) 
□feel better informed 
□have access to strategies (condoms, HIV testing, lube) 
□be assertive/confident 
□have strategies that are sexy/fit into sexual life 
□feel more motivated  
 
□have better concrete skills around negotiating strategies with partners 
□gain partner support 
□basic living needs met (housing, food, safety) 
□none could be identified 
□other, specify:  
 
6 STRATEGIZE: How to meet needs discussed? □ yes □ no  Sexual Health / Well-being Goal: 
STANDARD iNSC Tracking Forms (2 pages)  
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7 AGREE on: Strategy and Action Plan ? □ yes □ no 
_________________________________________________________________ 
 
Medication adherence – iNSC 
 
3 EXPLORE: Experiences with adherence. What has made adherence manageable/well integrated (PrEP easy)? What has challenged consistent 
PrEP use?  
Facilitators (said by participant) Challenges (said by participant) 
□match with routine/events 
□mobile/carry tools (e.g., pill box) 
□personal commitment (motivation) to staying HIV negative 
□memory aids/tools (e.g., alarm, calendar) 
□access  
□social support (partner(s), family) 
□feeling “at risk” 




□medication (too big, tastes bad) 
□disruption in routine 
□lack privacy 
□scared others will think HIV+ 
□side effects 
□feeling down/sad (not caring about protecting self) 
□feeling not at risk 
□memory or organization problems 
 □Partner or family member taking PrEP away 
□PrEP being stolen  
□none could be identified 




4 TAILOR: Level of engagement in this part of counseling:   □low  □medium  □high 
  
5 IDENTIFY or confirm needs:  Needs (What would make PrEP “easier”/manageable? What do current successful strategies DO for 
participant- what need do they meet? Select  all) 
□more information 
□have access to PrEP when needed 
□remember dose times 
□motivation (to feel like taking it, positive reasons to take it) 
□have privacy  
 
□manage side effects 
□social support 
□basic living needs met (housing, food, safety) 
□none could be identified 
□other, specify:  
 
6 STRATEGIZE: Strategies discussed? □ yes □ no  
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At [Clinic Name] we are providing integrated services for pregnant 
women involving their partners, family members, or other loved 
ones who are supporting them in their pregnancy. We ask you to 
visit the antenatal clinic so that we can provide you with important 
information to ensure the best care for your partner, family 






Date: ___________________Time: ______________ 
Room: ____________________  
 
You may come on another day (Mon to Fri)/time ([CLINIC 
HOURS]). 
 




INVITATION #: _____________ 
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OMUKHLUPILIRA NOMINATION FORM (SAMPLE) 
 
TRIAL 1 PARTICIPANTS: 
I, ___________________________, wish to nominate an individual to serve as my omukhulupilira, to help 
support my adherence to medicines for HIV treatment. I understand that, in order to serve in this role, the 
omukhulupilira will need to know my HIV status and that I am currently using antiretroviral medicines. 
 
 
TRIAL 2 PARTICIPANTS: 
I, ___________________________, wish to nominate an individual to serve as my omukhulupilira, to help 
support my adherence to medicines for HIV prevention. I understand that, in order to serve in this role, the 
omukhulupilira will need to know that I am currently using pre-exposure prophylaxis (PrEP) for HIV prevention. 
 
I expect to invite the following person as my omukhulupilira, who I will ask to attend the Omukhulupilira 
Orientation Session: 
 
ID information for omukhulupilira 
Name/Nicknames  
Relationship to participant  
Gender  
Age (approximate)  
Brief physical description (optional)  
Phone number (optional)  
 
If this person is unavailable, I may send the following alternate person(s) to attend: 
ID information for omukhulupilira: alternate 1 
Name/Nicknames  
Relationship to participant  
Gender  
Age (approximate)  
Brief physical description (optional)  
Phone number (optional)  
 
ID information for omukhulupilira: alternate 2 
Name/Nicknames  
Relationship to participant  
Gender  
Age (approximate)  
Brief physical description (optional)  
Phone number (optional)  
 
 
________________________________________     ____________________ 
PARTICIPANT SIGNATURE OR FINGERPRINT     DATE 
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INVITATION # ISSUED: _________________ 
OMUKHULUPILIRA ORIENTATION VISIT 
Lay support for each participant’s adherence to ART or PrEP is an integral component of the Tonse Pamodzi 
intervention. Social support from an important person in the participant’s life can greatly reinforce their own 
individual efforts to take their medication by the prescribed schedule. The omukhulupilira is a partner, family 
member, or friend selected by the participant to support their adherence to ART/PrEP outside of study visits. 
They may also take part in adherence strategy-building following iNSC sessions at the clinic, depending on the 
participant’s preference. Prior to this visit, the participant will nominate someone to attend this orientation visit 
(see Section 3 in Enrollment Visit section). 
To help the omukhulupilira in this role, this orientation session is designed to educate them about ART/PrEP 
and their role in supporting the participant’s use of ART/PrEP, and to coach them in the best ways of providing 
this support. This section includes the orientation visit procedures and the orientation visit checklist 
The scripts provided below are examples only. The Orientation Visit Checklist and the corresponding headers 
provided in the text indicate the necessary components of the session. 
 
1. INTRODUCING THE ORIENTATION VISIT 
Check in and build rapport 
[Begin by checking in and building rapport with the person. Then introduce yourself and the session]. 
 
Confirm omukhulupilira identity (if participant not present) 
The participant is encouraged to accompany the omukhulupilira to the site for this orientation. This is to 
reduce problems with proper identification and issues around HIV status or ART/PrEP use disclosure. 
However, if they were unable to accompany the omukhulupilira, be sure to begin by verifying the 
omukhulupilira’s identity using the instructions below. 
If the participant is not present, ask the person to state the name of the participant who sent them, their 
name, and their relationship to the participant. Verify this information as well as their physical description, 
approximate age, and gender against the omukhulupilira ID information provided by the participant. Only 
proceed with the visit if you are able to verify their identity as one of the possible supporters named by the 
participant. 
If the participant is present, you do not need to verify the identity of the omukhulupilira as above, but check 
with the participant first that the person they have brought with them is the individual they want to be their 
omukhulupilira. This can be done privately when the participant first arrives.  
Once the person is confirmed by the participant as the intended omukhulupilira, record the omukhulupilira’s 
gender and relationship to the participant in the appropriate fields of the Orientation Visit Checklist. 
 
Confirm disclosure of HIV status (if applicable) and ART/PrEP use 
Ascertain if participant has disclosed HIV status (if applicable) and ART/PrEP use to the supporter. Be 
careful not to disclose any information about HIV status or medications on behalf of the participant. 
 
If participant is present, in private conversation to confirm omukhulupilira selection: 
• Ask if she has already disclosed her [if applicable] HIV status and ART/PrEP use with the 
omukhulupilira. 
• If she HAS NOT disclosed, make sure the woman is aware the counselor cannot disclose on her 
behalf 
I do not have the right to disclose your HIV status or ART/PrEP use, but I can help to guide the 
conversation to help you disclose. Do you want to disclose in my presence? 
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If participant is not present, ask the person to explain what they understand about the purpose of their visit 
to the clinic. Probe on whether support for health or medication was mentioned. If disclosure has not 
occurred, conduct brief discussion of pregnancy support and close session (see below). 
Would you tell me what [Name of Participant] told you about the purpose of this visit today? 
 
If the participant has not disclosed and is either not present or does not wish to disclose the above, explain 
to the prospective omukhulupilira that this is a check in to see how the pregnancy is going. Engage them in 
a discussion regarding: 
• Their understanding of issues the participant may be facing in their pregnancy 
• If there is any way that they can help to support the participant in their pregnancy 
• If there is anything the clinic can do to better support the participant in their pregnancy 
 
Provide session overview 
When HIV status and/or ART/PrEP use disclosure is confirmed, proceed: 
So, as we’ve discussed, [Name of Participant] asked you to support her in taking [ART/PrEP]. We are 
calling people like you in this role “omukhulupilira.” 
Would you tell me a little bit about your relationship with [Name of Participant]? 
How do you feel about being asked to play this role and help [Name of Participant] in this way? 
Thank you for sharing. It’s important to me to know your questions and concerns about being an 
omukhulupilira for your [family member/partner/friend], and we will take the time to address these issues 
over the course of our conversation today. We’ll begin the session by providing you with information about 
[ART/PrEP], and why taking it every day as prescribed is so important. Then we’ll talk about what is 
expected of you as an omukhulupilira, and talk about the ways that you can best support [Name of 
Participant]. Finally, we’ll talk about what happens next after this visit, and the steps you can take between 
this visit and the next to support [Name of Participant]. 
Before we begin, are there any questions you have for me?  
 
Discuss importance of confidentiality 
Ask supporter to agree to confidentiality and allow questions before proceeding 
In this session we’ll be discussing [Name of Participant]’s [ART/PrEP] use and ways that you may support 
her to take this medication every day. It is very important that you do not share the information we discuss 
today with anyone besides [Name of Participant] unless she gives you permission. Specifically, it is 
extremely important that you do not disclose [Name of Participant]’s [if applicable: HIV status] or 
[ART/PrEP] to anyone else unless she says it is okay. 
Sometimes, this disclosure can be accidental; you may be excited about what you learn here about 
[ART/PrEP] and want to share this information with others. If this is the case, it is imperative that you don’t 
share the context in which you learned this information. That is, do not disclose that you learned this 
information in connection with [Name of Participant]’s care or this program. 
Using [ART/PrEP] or [if applicable: living with HIV] is nothing to be ashamed of, but sharing this information 
with people can lead to reactions that someone may not want or may not be ready to deal with. For these 
reasons, it’s extremely important that [Name of Participant] be able to choose if she wants to share this 
information with anyone else, and who to share it with. 
Do you agree to keep this information confidential?  
Do you have any questions about this before we move on?  
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2. EDUCATION ABOUT HIV AND ART/PREP 
Review ART/PrEP information table 
*Refer to participant education materials and procedures. Note to the participant (if present) that this will be 
a review for them. Examples from the Tonse Pamodzi 2 trial are included in the Appendices. 
Afterwards, ask if the omukhulupilira has any questions before moving on. 
 
3. THE ROLE OF THE OMUKHULUPILIRA 
Define expectations of omukhulupilira  
Now that you know about [ART/PrEP] and why it’s so important to take it every day, let’s talk about what 
you are being asked to do to support [Name of Participant]’s adherence to [ART/PrEP]. 
There is no one right way to support adherence to [ART/PrEP], and so you are being asked to be part of a 
collaborative process to find the best strategies for [Name of Participant] to maintain adherence centered 
around her individual needs and preferences. Because every person is different, these strategies will look 
different for each person. So, while we can’t tell you exactly what the strategies will be, we can tell you 
what the basic expectations will be of you as an omukhulupilira. These are: 
• To help [Name of Participant] put into practice the adherence strategies she develops with the study 
counselor, and provide any other support appropriate to help her take [ART/PrEP] every day. 
• Depending on [Name of Participant]’s needs, she may invite you to participate in up to 3 adherence 
counseling sessions to help her develop strategies to overcome problems she might be having with 
adherence. 
 
Seek agreement to serve in this role 
I want to take this opportunity to see if you think you are able to play this role: 
• Do you think you will be able to meet with [Name of Participant] regularly outside of these sessions to 
provide this support? 
• Do you think you will be able to meet with her in a private location? 
• What types of places/times might you meet? 
Given what we’ve discussed, are you willing to serve as [Name of Participant]’s omukhulupilira? 
 
Discuss importance of adherence support and common adherence barriers 
The following includes additional education, to be conducted in a participatory manner. Try to engage the 
omukhulupilira through a series of questions and answers to better engage them in the topics covered. 
First let’s talk about why your support is so important to help [Name of Participant] adhere to [ART/PrEP]. 
Can you tell me about something that you have to do or have had to do on a daily basis that might seem 
simple but is actually difficult to keep doing every day?  
[If participant has no ideas, prompt to think about common tasks. For example, for men, this may include 
finding work in order to provide for the family. For women, this may focus on cooking for the family.] 
Would you tell me why it [is/was] difficult to do every day? 
What do/did you do to make it easier, if anything? Did anyone help you? 
 
As you can see just because a task might seem simple, like taking a pill, if we have to do it every day it 
might become difficult to maintain. Finding ways to overcome these difficulties, often with the help of family 
or friends, is essential to being able to complete the task every day. 
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While everyone is different, there are many common difficulties that people may face in being able to take 
[ART/PrEP] on a daily basis include [give examples from table below]: 
 
Common barriers to PrEP adherence Common barriers to ART adherence 
• Disruption in routine 
• Dislike of medication (too big, tastes bad) 
• Lack privacy 
• Scared others will think HIV+ 
• Side effects 
• Feeling down/sad (not caring about 
protecting self) 
• Feeling not at risk 
• Memory or organization problems  
• Alcohol/drugs 
• Disruption in routine 
• Dislike of medication (too big, tastes bad) 
• Lack privacy 
• Scared others will find out HIV+ 
• Side effects 
• Feeling down/sad (not caring about 
protecting health) 
• Memory or organization problems  
• Alcohol/drugs 
• Feel sick   
• Feel healthy 
 
 
Now let’s talk about how support from a [family member/partner/friend] like you would help someone 
overcome these barriers. First let’s take the example of forgetting – if [Name of Participant] were having 
trouble remembering to take her medication on time every day, what are some things you would do to help 
her, or advice you would give her?  
 
Thank you, now let’s take the example of feeling sad, down, or discouraged – if [Name of Participant] were 
feeling this way, what are some things you would do to help her?  
 
Allow for questions 
Do you have any questions about this before we move on? 
 
4. WAYS OF PROVIDING SUPPORT FOR PrEP/ART ADHERENCE 
The right way to support someone will depend on their needs and the relationship you have with them, but it 
may be helpful to think through some of the basic ways you can provide meaningful support. These fall into 3 
basic categories: 
1) Emotional support, or providing expression of empathy, acceptance, love, trust, or care  
2) Instrumental support, or providing tangible aid or service 
3) Informational support, or providing advice, suggestions, or information 
Let’s talk about each of these in more detail: 
 
Discuss emotional support and empathy 
Emotional support (Expressions of empathy, acceptance, love, trust, and care) 
Before we talked about one example of providing support for someone who is feeling sad, depressed, or 
discouraged. Can you think of any other ways of providing emotional support to help [Name of participant] 
maintain adherence to [ART/PrEP]? [Allow person time to respond] 
Thank you for sharing that, there are a lot of ways of providing emotional support to help with adherence, 
but some of the most common ways include: 
o Emotional support for any source of distress 
o Providing encouragement to take medication when the person is feeling discouraged 
o Letting them know that you care about their health and wellbeing 
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An important principle to keep in mind when providing emotional support is empathy, or seeking to 
understand rather than judge. [Name of Participant] may share person problems and emotions with you not 
only as part of your existing relationship, but in your new role as omukhulupilira. When she shares these 
sensitive topics with you, it’s important that you try to receive the information with empathy, or 
understanding of and sympathy for the feelings and problems that she is sharing rather than disinterest or 
judgement. 
o Say for example that [Name of Participant] tells you that her husband is angry with her and has 
been yelling at her a lot. 
§ Here are some examples of unhelpful ways of responding: 
• [Disinterested] “That happens to me all the time it’s part of life, you just have to 
deal with it.” 
• [Judgmental] “You must have done something to make him angry, you should be 
more careful in the future.” 
§ Would you tell me what is wrong with both of these responses? [Allow person time to 
respond] 
o Can you think of a more positive and empathetic way of responding? [Allow person time to 
respond] Thank you for sharing that example, here are a couple of others: 
§ I’m so sorry to hear that you’re going through that. I’m here to help. 
§ This must be really difficult, thank you for sharing with me. 
 
Discuss instrumental support and non-punitive support 
Instrumental support (Tangible aid and service) 
Before we talked about one example of providing support for someone who has difficulty remembering to 
take their medication every day, on time. Can you think of any other ways of providing day to day, practical 
support to help [Name of participant] maintain adherence to [ART/PrEP]? [Allow person time to respond] 
Thank you for sharing that, there are a lot of ways of providing instrumental support to help with adherence, 
but some of the most common ways include: 
o Help with transport or transport money to medical appointments 
o Help picking up prescriptions if you are their guardian 
o Providing childcare so person can attend medical appointments 
o Bringing someone water to take their pills with 
 
Non-punitive support  
There are some ways of encouraging [Name of Participant]’s adherence to [ART/PrEP] that may seem like 
good ideas but should be avoided. Specifically, using punishments like you might use for a child to 
encourage [Name of Participant] to take [ART/PrEP] every day is not a good approach because it may hurt 
her own motivation to use [ART/PrEP] by making her feel powerless. The most extreme approaches like 
this, such as threatening or using physical violence, will cause much more harm than good and must be 
avoided. Some examples of other things not to do: 
o Saying mean or hurtful things if she does not take her medication 
o Expressing anger or yelling 
o Threatening to or actually withholding food or other material needs if she does not take her 
medication 
o Not talking to her because she did not take her medication 
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Discuss informational support and patient-centeredness 
Informational support (Advice, suggestions, and information) 
The last kind of support we’ll talk about is informational support, or providing advice, suggestions, or 
information to help a person. One major way you can help with informational support is by participating in 
adherence counseling sessions with [Name of Participant] to help her think of strategies to help her take 
[ART/PrEP] every day and on time. Can you think of any ways that you could provide advice or 
suggestions to her outside of these counseling sessions that could help with her adherence? [Allow person 
time to respond] 
Thank you for sharing that, there are a lot of ways of providing informational support to help with 
adherence, but some of the most common ways include: 
o Medication taking reminders 
o Daily check-in to see if took medication 
o Reminding the person of why it is important to them to take the medication every day 
o Help acquiring information from clinic staff regarding medication taking between appointments 
 
Participant-centeredness 
When you provide instrumental or informational support, always keep in mind that while we may each have 
our own ideas about the best way to do things, it is important that we put the needs, perspective, and 
opinions of [Name of Participant] before our own. While your role as omukhulupilira is to help [Name of 
Participant] develop strategies to be able to take [ART/PrEP] every day, and help her to carry out these 
strategies after the counseling sessions, it’s important to allow [Name of Participant] to determine with your 
assistance how she wants to be helped to rather than deciding on your own how you might be most helpful. 
Let’s talk about one example: [Name of participant] tells you she hasn’t taken her medication for the past 
few days. 
o Here is an example of a handling the situation that puts your ideas before hers: “That’s not 
good, I know that taking your medication every day can be hard but what you really need to do 
is be sure to take your pill every day when you eat dinner so you will not forget.” What’s wrong 
with this response?  [Allow person time to respond] 
o In contrast, here’s a way of supporting the person that puts their needs and ideas first: “What 
are the reasons that you weren’t able to take your medication? I’m sorry to hear that, what do 
you think would make this easier? What can I do to help you?” 
 
Allow for questions 
Do you have any questions about this before we move on? [Give the person time to respond] 
 
 
5. FACILITATING INITIATION OF SUPPORT 
At this point I hope you understand the basic ways that you can help [Name of participant] as an 
omukhulupilira. Do you have any questions for me at this point? 
 
Plan for private meetings between omukhulupilira and participant 
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Meeting with participant and confidentiality 
Before we talked about the importance of confidentiality, or keeping sensitive information private. Would 
you tell me what you remember about this? [Allow person time to respond] 
Yes, it’s very important to not talk about the following things to other people unless [Name of Participant] 
gives you permission 
- HIV status 
- Her use of [ART/PrEP] 
- Her and your participation in this program 
- Discussions related to these topics 
 
To preserve the confidentiality of this information, it’s important to think through if and how you will be able 
to meet with [Name of Participant] privately so you can talk about [ART/PrEP] without anyone hearing your 
conversation who she would not want to have hear it. 
[Involve participant in discussion if present]  
• Where do you think you can meet to speak comfortably in private, so that people will not overhear? 
• When would you be able to meet in private? 
[If participant not present]  
• How do you think you will make a plan with her for these private meetings?  
• When will you do this? 
 
 
Develop action steps for first support discussion with participant 
 
Having the first support conversation (if participant present) 
 
Now that you have a meeting plan, let’s talk about how you can get started supporting [Name of participant] 
Desired support: [Ask of participant]  
• Do you have any initial ideas of how [Name of Supporter] could be most helpful to support your 
adherence to [ART/PrEP]? [Allow person time to respond, provide suggestions if needed] 
• How have you provided support to each other in the past?  
• How could you apply that to this situation? 
Support to offer: [Ask of Supporter]  
• What do you think are the main ways, including or in addition to those already mentioned, that you 
feel able to support [Name of participant]? 
 
Planning future check-ins: [To both]  
• Now that you have this understanding, what do you think it would be most helpful to talk about next 




Planning the first support conversation (if participant not present) 
 
Now that you have a good idea of how and when you will meet with [Name of Participant], let’s talk about 
how to have the first conversation about supporting her use of [ART/PrEP]. 
 
 
Questions to ask:  
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• What questions would you ask of [Name of participant] to better understand how she would want to 
be supported?  
• Those are all great ideas; which two questions do you think will be the most important for you to ask 
[Name of participant] first?  
 
 
Support to offer:  
• Great, these questions will help you figure out how you can best help [Name of Participant]. What 
are some types of support that you could offer to her during this conversation? [Allow person time to 
respond, provide suggestions if needed] 
 
Planning future check-ins:  
• Once you understand how [Name of Participant] wants to be supported, how will you decide when 
to talk next at a private setting and time? 
 
Allow for questions 
Do you have any concerns about having your [first/next] conversation? [Allow person time to respond, trouble-
shoot issues that arise] 
 
6. CLOSING THE SESSION 
Thank for participation 
Thank you very much for coming today and for your active participation in our session today. 
 
Allow for final questions  
Before we close the session, do you have any other questions or concerns? [Allow person to ask questions 
and provide responses, for questions that you are unable to answer, ask for their contact information and say 
that you will follow-up with an answer, or you can provide the response at the next visit] 
 
Provide contact information 
Don’t hesitate to contact us if you have any other questions or concerns about your role as omukhulupilira 
[Provide contact information]. You can also discuss any questions or concerns if you come with [Name of 
Participant] to her next counseling session. 
 
Thank you again for your participation and for agreeing to serve as an omukhulupilira. Please discuss with 
[Name of Participant] if you should attend the first counseling session on [date and time of scheduled 
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ORIENTATION VISIT CHECKLIST 
Date (DD/MMM/YYYY) |___|___|/|___|___|___|/|___|___|___|___|                     Start time ___ ___: ___ ___ 
Participant ID |___|___|___|___|___|     Staff ID |___|___|___|  
Omukhulupilira gender:   Male       Female 
Omukhulupilira relationship with participant: ____________________ 
Participant present?   Yes       No 
⃝ 1.  Introducing the counseling visit  
  Check in and build rapport 
  Confirm omukhulupilira identity (if participant not present) 
  Ascertain disclosure of HIV-status (if applicable) and ART/PrEP use 
  Provide session overview 
  Discuss importance of confidentiality 
  Allow for questions 
 
⃝ 2. ART/PrEP education 
  Review ART/PrEP information table 
  Allow for questions 
 
⃝ 3. Role of the omukhulupilira 
  Define basic expectations of omukhulupilira  
  Seek assent to play this role 
  Discuss importance of adherence support and common adherence barriers 
  Allow for questions 
 
⃝ 4. Ways of providing support for PrEP/ART adherence 
  Discuss Emotional support, empathy 
  Discuss Instrumental support, non-punitive support 
  Discuss Informational support, person-centered support 
  Allow for questions 
 
⃝ 5. Facilitating initiation of support 
  Plan for private meeting omukhulupilira and participant 
  Develop action steps for first support discussion with participant 
  Allow for questions 
 
⃝ 6. Closing session  
  Thank for participation 
  Allow for final questions 
  Provide contact information 
 
 






End time ___ ___: ___ ___  
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ADHERENCE CHECK-IN VISITS (MONTHS 1 & 3) 
 
SESSION COMPONENTS 
Participants assigned to the intervention condition will have follow-up iNSC sessions during Month 1 and 3 
visits. The aim of these visits is to follow up on the goals set during the previous iNSC sessions, first 
individually and then—if the participant is accompanied—with the omukhulupilira. During this part of the visit, 
participants will be asked to engage in the following four general phases of interaction: 
 
1. Welcome  
2. iNSC  
3. Joint session with omukhulupilira (if accompanying participant) 
4. Close session with plan for next steps 
 
1. WELCOME 
The session begins with a general welcome and an overview of the discussion. 
 
Welcome and thank you for coming to this follow up visit. I look forward to hearing about how things 
went these past weeks!  I also want to learn more about your journey on ART/PrEP. 
The intervention counselor should note whether the participant has chosen an omukhulupilira and whether this 
individual has accompanied her to the visit. This will help to frame the discussion in the iNSC component. The 
participant should also be given the option of inviting the omukhulupilira to join the counseling session following 
the individualized iNSC discussion. 
 
2. iNSC  
Similar to the enrollment visit, the iNSC component of the session includes two parts. The first part is a broader 
discussion about general well-being. The second part focuses in on use of [ART/PrEP], including challenges 
and facilitators of adherence. This is a direct discussion about how to achieve and maintain medication 
adherence. All intervention counselors will train in the conduct of iNSC, using the iNSC Workbook (see 




Introduce Explain what you want to discuss, why, and ask permission  
Ask if it is okay to split the discussion into two parts -- first about general well-being and then 
about adherence.  
Steps below will be repeated for each component. 
Review Check in on previous goals/discussions, close and move into current experiences 
Explore Discuss socio-ecological factors that challenge or could optimize a specific behavior 
Tailor Reflect on context and experiences shared to tailor remainder of the discussion 
Identify Ask what would be needed to happen for the behavior (identified above) to be easier to handle or 
be more manageable  
Strategize  Ask how the participant might consider addressing this need 




Move to a new topic and repeat the flow OR close the discussion  
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3. JOINT SESSION WITH OMUKHULUPILIRA 
Participants accompanied by their omukhulupilira will be given the option of a joint session following the 
individualized iNSC session. This is voluntary. The purpose of this joint session is to engage the omukhulupilira 
in identifying and addressing challenges to medication adherence.  
Participants who elect to have this joint session are asked—at the end of the iNSC session—to identify the 
issues they would like to discuss with their omukhulupilira in the room. These should be issues they are 
comfortable discussing with the omukhulupilira. This will serve as a guide for the session. 
The joint session with omukhulupilira will be condensed to only three steps of the iNSC framework: review, 
strategize, and agree (see below). The intervention counselor encourages engagement of the omukhulupilira 
and ensures that he/she is given the opportunity to share observations and experiences in a manner that 
fosters joint problem-solving.  
 
Step Description 
Review Review the main issues identified by the participant for discussion regarding medication 
adherence  
Strategize  Ask the omukhulupilira and participant how this issue might be addressed 
Agree  Ask the omukhulupilira and participant if they would agree to try out one or more strategies to 
address the identified need 
 
For participants who did not previously select an omukhulupilira, the option should be presented again.  
Last time you were here we talked about the option to train someone to help you with your medication 
adherence. This person is called the omukhulupilira. Do you remember what this is? [re-explain role if 
needed] 
I know that last time you were here it didn’t make sense to pick an omukhulupilira at that time. You still 
don’t have to select an omukhulupilira but we want to give you the opportunity again each time you 
come in. Would it be okay with you if we take a few minutes now to discuss this option again to 
consider if you want to select an omukhulupilira today?  
 
If participant expresses interest in choosing an omukhulupilira, refer to Enrollment Visit Section 3. If 
permission not granted, then continue to closing the session. 
 
4. CLOSE THE SESSION WITH PLAN FOR NEXT STEPS 
Provide a summary of what was discussed, thank the participant and remind her of the next visit. 
You noticed that [reiterate a key strategy from iNSC discussion] would really make it feel easier to work 
[ART/PrEP] into your life and that [reiterate a key strategy from iNSC discussion] is something that will 
help with that. You’ll give that a try between now and the next time we meet.  
Thank you for talking with me. I look forward to talking again when you come in next time. 
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ADHERENCE MAINTENANCE VISIT (MONTH 6) 
 
SESSION COMPONENTS 
The aim of this final visit is to identify new barriers to medication adherence and how to address them. It is also 
to summarize those strategies that have been used and provide the participant with some insights into 
continued engagement in this problem-solving approach. 
1. Welcome  
2. iNSC  
3. Joint session with omukhulupilira (if accompanying participant) 
4. Close session with plan for next steps 
 
1. WELCOME 
The session begins with a general welcome and an overview of the discussion. 
 
Welcome and thank you for coming to this follow up visit.  For this conversation together, I am hoping to 
spend some time getting to know how things have been going since the last visit. I also want to learn 
more about your journey on ART/PrEP. 
 
The intervention counselor should note whether the participant has chosen an omukhulupilira and whether this 
individual has accompanied her to the visit. This will help to frame the discussion in the iNSC component. The 
participant should also be given the option of inviting the omukhulupilira to join the counseling session following 
the individualized iNSC discussion. 
 
2. iNSC  
Similar to the enrollment visit, the iNSC component of the session includes two parts. The first part is a broader 
discussion about general well-being. The second part focuses in on use of [ART/PrEP], including challenges 
and facilitators of adherence. This is a direct discussion about how to achieve and maintain medication 
adherence. All intervention counselors will train in the conduct of iNSC, using the iNSC Workbook (see 




Introduce Explain what you want to discuss, why, and ask permission  
Ask if it is okay to split the discussion into two parts -- first about general well-being and then 
about adherence.  
Steps below will be repeated for each component. 
Review Check in on previous goals/discussions, close and move into current experiences. 
Explore Discuss socio-ecological factors that challenge or could optimize a specific behavior 
Tailor Reflect on context and experiences shared to tailor remainder of the discussion 
Identify Ask what would be needed to happen for the behavior (identified above) to be easier to handle or 
be more manageable  
Strategize  Ask how the participant might consider addressing this need 




Move to a new topic and repeat the flow OR close the discussion  
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3. JOINT SESSION WITH OMUKHULUPILIRA 
Participants accompanied by their omukhulupilira will be given the option of a joint session following the 
individualized iNSC session. This is voluntary. The purpose of this joint session is to engage the omukhulupilira 
in identifying and addressing challenges to medication adherence.  
Participants who elect to have this joint session are asked—at the end of the iNSC session—to identify the 
issues they would like to discuss with their omukhulupilira in the room. These should be issues they are 
comfortable discussing with the omukhulupilira. This will serve as a guide for the session. 
The joint session with omukhulupilira will be condensed to only three steps of the iNSC framework: review, 
strategize, and agree (see below). The intervention counselor encourages engagement of the omukhulupilira 
and ensures that he/she is given the opportunity to share observations and experiences in a manner that 
fosters joint problem-solving.  
 
Step Description 
Review Review the main issues identified by the participant for discussion regarding medication 
adherence  
Strategize  Ask the omukhulupilira and participant how this issue might be addressed 
Agree  Ask the omukhulupilira and participant if they would agree to try out one or more strategies to 
address the identified need 
 
 
4. CLOSE SESSION WITH PLAN FOR NEXT STEPS 
Provide a summary of what was discussed. Remind the participant that this is the last scheduled intervention 
session and review the main issues identified and addressed through the counseling sessions. Discuss ways 
in which these could be applied for continued medication adherence following the study. 
As you know, this is the final scheduled visit for the intervention part of this study. Through this process, 
you identified strategies that could improve your adherence. These include [reiterate key strategies 
from the iNSC discussions] that would make it feel easier to work [ART/PrEP] into your daily routine. I 
would encourage you to continue trying these ways to ensure that you take medicines on a daily basis. 
Discuss future steps for continuing ART/PrEP use, including transition to the standard of care. Details of this 
discussion and guidance will be site-specific but should include: 
• For women living with HIV on ART: 
o Encourage women to discuss their perceived challenges about transitioning to standard of care 
and how those issues might be addressed. 
o Provide information and resources about continuing support for ART adherence as appropriate. 
• For HIV-negative women on PrEP: 
o Discuss desire to use PrEP after study close, either in the immediate or future. Provide 
information about local PrEP resources. 
o Encourage women to discuss their perceived challenges about transitioning to standard of care 
PrEP services and how those issues might be addressed. 
o Provide information and resources about continuing support for PrEP adherence as appropriate. 
 
Close by thanking them for their participation. 
I hope your participation has been helpful. Thank you again for talking with me. 
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Using this Workbook 
Welcome to the Next Step Counseling workbook. Here, we review the basic and advanced ideas 
underlying Next Step Counseling (NSC) and integrated Next Step Counseling (iNSC). After an 
introduction to what Next Step Counseling does, and doesn’t do, and how it was developed, we review 
the communication skills needed to engage in NSC or iNSC discussions. This workbook has suggestions 
for trying these out in TRY IT spaces. Each step in NSC is then unpacked, with examples in italics and 
TRY IT opportunities. We then expand NSC to its use with multiple health-related topic areas. With 
integrated Next Step Counseling facilitators can engage people in conversations that include related 
but unique topics- like general well-being and adherence to a prescribed medication, sexual health and 
persistence with a given therapy, or decision making and maintaining health. We intentionally try to 
adopt a general explanation of the approach which can be applied to any number of health-related 
behaviors and strategies to promote well-being. Concrete examples are provided in the areas of HIV 
prevention and treatment. We encourage learners to use the workbook EXERCISES to adapt the 
approach to be most useful to their particular areas of interest. Because all person-facing approaches 
are highly context driven and dynamic (always changing), we provide recommendations for monitoring 
how NSC and iNSC is delivered and received in practice.     
Learners 
NSC and iNSC facilitators have to be willing and open to working with people “where they are at”, 
which involves giving up relational power, adopting shared decision making, and doing a whole lot of 
listening. Depending on people’s beliefs, views about their role, and views about the people they work 
with and for, this can be more or less challenging.  In this workbook, we assume no formal training in 
counseling or communication. That is why we use many TRY IT and EXERCISE opportunities 
throughout. We DO however recommend that learners work with each other to refine skills and 
connect with NSC or iNSC facilitators who have some experience using the approach. No matter what 
your background is or where you are using NSC or iNSC, we believe anyone can implement parts of or 
the complete approach. Commitment, practice and willingness to learn are the core determinants for 
learning the approach.   
Learning Objectives 
People completing this workbook in full, including the activities, should: 
 Feel confident in their understanding of the underlying rationale for NSC and iNSC 
 Be able to use basic and advanced communication skills 
 Be able to facilitate NSC and iNSC discussions 
 Use the self-monitoring tool 
 Gather implementation feedback from people engaged with them in NSC or iNSC discussions 
 
A NOTE ON LANGUAGE 
This workbook is written in American English. We use facilitator to identify the person/people 
implementing NSC/iNSC, learner to identify the person/people using the workbook, and person/people 
engaged in NSC/iNSC discussions to identify those facilitators are working with (eg., participants, 
patients, participants, so on).  
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How is it any different than other kinds of health-related discussions? 
NSC should share a number of similarities with patient-centered, strengths-based counseling, and 
draws heavily from the tenets of Motivational Interviewing (MI) and some of the strategies used in MI. 
Basic and advanced communication skills are also part of NSC. Exploring barriers and coming up with 
strategies to address those is common in many brief counseling approaches.  NSC is unique from some 
approaches that prescribe specific content. NSC is a process approach, a format to a conversation and, 
as such, can be applied to any number of issues or areas. While we see considerable synergies with 
other approaches, we feel the following have been identified by practitioners and learners as offering 
specific value: 
 
(1) Supports flexibility in discussions- the process of exploration to something more concrete like a 
specific strategy or action plan is recommended, but what that looks like, skills you may use, 
communication styles, and content, are all tailored to the person. 
 
(2) Supports use and dissemination of theory- Exploration draws on the Socio-ecological model and the 
situated Information, Motivation, Behavioral Skills model and aspects of Motivational Interviewing 
concepts and skills are used in training facilitators and can also be explicitly shared with the people they 
engage during exploration and strategizing. 
 
(3) Shares power with people engaged- Conversational power and a person’s autonomy feature 
prominently in the approach and are highlighted as reasons for a number of the steps, including the 
identification of a “next step” 
 
(4) Emphasizes that people engaged can and do come up with their own needs, strategies and 
plans- Facilitators “hold-back” on recommending courses of action, preferring to guide people towards 
their own identification of needs, strategies and plans 
 
(5) Works specifically with “needs” not barriers- Facilitators help people to identify one or more 
need- an underlying condition that facilitates or even drives a downstream behavior.  
 
(6) Is a guided conversation versus message delivery or providing “counsel”- Facilitators talk with 
people. There is an exchange of information and expertise. Power is shared in this regard. 
Counsel (telling someone what they should do) is not part of the approach. 
 
(7) Acknowledges limits of discussion-based person-facing approach- NSC depends on open 
engaged communication. If people do not want to share or want to share only parts of their 
realities or experiences, that is their decision and we cannot force people to be open, or engaged 
or even honest. We rely on the person to share- so creating welcoming and conducive 
environment for this is our first job and responsibility. We cannot, however, control whether or 
not people want to use those environments. The level at which someone engages in up to them. 
We do not know the truth of someone’s experiences, only what they decide to share. 
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Facilitators use skills and approaches that make NSC/iNSC...  
 Client-Centered 
o The person is the expert on her life and behaviors. 
 Comprehensive (Multi- targeted) 
o Providing accurate information is necessary but insufficient to produce behavior change or promote 
engagement in discussions about product use. Motivation (personal and social) and skills are also critical to 
help produce change. 
 Context-Driven 
o The session explores the context in which one negotiates next-steps. It is not focused on ‘failure’ events 
(e.g., times when the person did not exercise, did not dose, or did not show up to care) or on the 
identification of barriers (e.g., attributions or reasons for failures). The focus is on the aspects of a topic 
that contextualize one’s experiences with it which can elicit the identification of some needs people may 
have that when addressed could move the person from their present to an improved situation through 
some identified strategy. 
 Genuine 
o The facilitator maintains a genuine interest in the person and reflects that interest through exploration of 
the person’s experiences. Facilitators seek to remain aware of their bias and judgments and seek to be 
responsive to the person and their engagement in the conversation. 
 Guided 
o The facilitator guides the discussion through questioning, and does not do most of the ‘talking’. The person 
should have the majority of ‘talk time’ in any given session. 
 
 Individualized 
o The discussion is individually tailored to the levels of engagement and context of a given person at a given 
point in time. 
 Neutral (In Stance) 
o The facilitator maintains a supportive but neutral stance throughout the session to convey acceptance of 
both the person and their disclosures of positive and negative aspects around adopting or trying to adopt 
certain behaviors. 
 Recognizes Limited Role 
o The facilitator recognizes that their impact is in the immediate session and that they cannot “make” people 
do anything. They can, however, ensure that a safe environment is consistently provided for people to 
engage and discuss their experiences. 
 Strengths Based 
o Discussions about experiences, needs and strategies are appropriate across the full spectrum of behavior 
adoption. Someone need not have challenges for the discussion to proceed. The conversation is flexible to 
promoting behavior change or promoting maintenance of an established strategy/strategies. 
 
  
The Mindful Facilitator 
 
One of the most important skills is to become aware of yourself… your reasons for asking 
participants specific questions, your body language, your expectations and biases, and your 
‘session planning’. Often, we engage in a process- it is not one question and one answer (that is 
assessment or interviewing). Asking a question, reflecting or summarizing should have a reason in 
your mind. Take your time. Think about why you would go some particular direction in a 
conversation rather than other directions. Watch yourself and ask others to watch you. Being 
mindful of your own processes, as well as the participants, distinguishes good from excellent 
facilitators. 
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EXAMPLES OF NSC FACILITATOR PROMPTS 
STEP FEATURE HIV Medication Adherence Diabetes Self-Care 
Introduce 
Promote shared decision making and balance of power 
by sharing what you are hoping to discuss and asking 
permission 
Now I’d like to talk about your medication use. Is 
that okay? 
Are you comfortable talking about nutrition and exercise 
now? 
Review 
Anything to check in on? Information or education from 
other people they have met with today, experiences 
with ‘counseling’, or past goals from previous sessions? 
Last time we talked a lot about what makes 
taking your meds easy and challenging. You came 
up with some strategies to make it easier. What, 
if anything, have you tried?  
Last time you shared that you would feel more confident 
managing your diabetes if you were eating more colorful 
meals and getting more physical activity. What, if 
anything, have you tried? 
Explore 
Things, situations, ways you feel, thoughts you have, 
your beliefs, other people’s beliefs, ways your 
community feels or treats people, resources available, 
systems of care, economics, political environment so on 
(all levels of Socio-ecological model) that help with 
TOPIC …that make it hard to TOPIC  
What kinds of things or ways you feel seem to 
make dosing feel manageable, or like something 
you can or want to do? 
What kinds of situations, thoughts or feelings 
make dosing feel really hard or like something you 
just can’t or don’t want to do? 
What kinds of situations, thoughts or feelings make 
preparing your own meals feel manageable, or like 
something you can or want to do?  
What things or ways you feel making preparing your own 
meals feel hard or like something you just can’t or don’t 
want to do? 
Tailor Facilitator factors in the person’s context and constructs a question that will focus the discussion on this person’s specific needs 
Identify 
Facilitator asks an appropriate question “WHAT would 
need to happen for TOPIC to feel just a little more 
manageable” 
What would need to happen for it to feel just a 
little more manageable to take your meds when 
you feel depressed? 
What would need to happen for it to feel just a little more 
manageable to prepare your meals during busy work 
weeks? 
Strategize 
Facilitator guides exploration of HOW the person could 
see the need identified being met, in part or in full 
How could you incorporate more movement into 
your day, especially when you’re depressed? 
How could you imagine receiving more support from 
those around you? 
Agree 
Facilitator guides identification of WHICH of the 
strategies the person is willing to try out and explores 
an action plan- checking in on how to monitor success 
of the strategy and adapt strategy explored. Remind 
person of NEED and that lots of other strategies may 
help with a given NEED. 
So you’ve come up with a few ideas – to walk your 
family dog each morning, to do at-home yoga 
videos, and to walk your sibling to the park – 
what would you like to try between now and the 
next time we meet?  Great. When you do try that, 
how will you know if it is helping? What will you 
do if it does not feel like it really is helping? 
So you’ve come up with a few ideas – splitting meal prep 
duties with your partner, making a list of healthy take out 
options, and reducing your weekend commitments to 
make more time for meal prep. What would you like to 
try between now and next time we meet? 
Close 
Facilitator provides a summary of the discussion (here 
are the things that help, here are challenges, here is the 
main need you identified, here is what you said you 
would try, using this specific plan), confirms, thanks and 
plans for next conversation. 
Ok, so you’d like to try taking the dog for a walk 
every morning and then take your meds when you 
return. Is that right? 
Alright. So it sounds like you want to start by asking your 
partner to cook dinner two nights a week and creating a 
list of healthy take out options so that you can still have a 
colorful meal when you’re in a time crunch. 
Is that right? 
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What does Integrated Next Step Counseling Sound Like? 
Let’s consider the example of working with someone who is coming to your clinic for PrEP services. 
You are using iNSC to introduce discussions about sexual health generally and PrEP adherence 
specifically. Read through the facilitators comments and questions. The step is noted at the end of the 
facilitators statement. 
I would like to take just a few more minutes to talk with you about sexual health and where you are at with 
PrEP. Does that sound OK? [INTRODUCTION] 
Last time we met, you said you would talk to your partner about agreements to be just with each other and 
also you were just starting with PrEP. How did that go for you? [REVIEW] 
Thank you. Let’s focus in on how things are going now.  
I want to learn more about how PrEP went for you, but can we focus first for a few minutes on the other 
things you are doing or thinking of doing to protect your sexual health besides PrEP? [SPLIT THE 
CONVERSATION] 
Can you share with me again – what your thoughts are about protecting your sexual health? Are there 
things you do for that, not including PrEP? [Establish current situation for TOPIC 1] 
I hear you saying that you are considering condoms with outside partners and also considering entering a 
monogamous arrangement with your boyfriend. What kinds of things, situation, things going on in the 
relationship or ways you think or feel make you feel like protecting your sexual health is someone 
accomplishable- not easy to do but easier? [EXPLORE TOPIC 1] 
And what would you say are the times, situations, thoughts or feelings that make protecting your sexual 
health feel hard to do or like something that just isn’t possible or gonna happen? [EXPLORE TOPIC 1] 
Facilitator reflects internally on the situation (that the person does use condoms in situations and is 
considering monogamy with a partner he cares a lot about), the facilitators reported (person reported 
feeling motivated towards condom use with outside partners when the relationship with his partner is 
strong and going well) and barriers (when he is in an argument with his boyfriend, when work is 
overwhelming, and when drinking he cares less about protecting his health in general). The facilitator 
decides to center a question about needs on motivation towards protecting himself as that seemed like 
a common theme. [TAILOR TOPC 1] 
In thinking about the situations you shared, what would you say would need to happen or be different for 
you to feel consistently motivated to protect your sexual health? If you could change anything, what would 
it be? What would be there or not there? What would need to be a little different? [IDENTIFY NEED TOPIC 
1] 
So, for you, feeling happier seems to be an important need. If you could feel happier more consistently, you 
feel you would be more motivated. How could you see that happening? How could you be happier more 
consistently? [STRATEGIZE TOPIC 1] 
You mentioned being in a more committed relationship would provide you happiness, and also said that 
when you are working out and eating well, you feel happier overall. Of those, is there one you could plan to 
address?  [AGREE TOPIC 1] 
You said going to the gym. What are the steps that go into that? What sequence of events leads to going to 
the gym? [ACTION PLAN for TOPIC 1] 
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So you have a plan for going to the gym to try to see if that helps with more consistent feelings of 
happiness, and from that motivation to take care of yourself. When you try that, how will you know if it is 
working as you wanted it to? What will you do if it feels like it is not doing what you thought it would?  
[CONFIRM plan and explore monitoring and adapting for strategy] 
Thanks so much. I know you got PrEP last visit and have been trying to take it I think? Where are you at with 
it right now- does it feel like a good choice for you? [TRANSITION AND ESTABLISH SITUATION FOR TOPIC 
2] 
OK- so you are feeling good about the decision. Can you share with me what situations or feelings seem to 
make taking a dose a day feel like it is easy- or easier- to do? [EXPLORE TOPIC 2] 
Thank you. What about things that make it feel like a challenge- even if you do it- things that make it just 
feel hard? [EXPLORE TOPIC 2] 
Facilitator reflects internally on situation shared (on PrEP, engaged and continuing with it), facilitators 
(shared partner is on PrEP as well and they dose together, reported no side effects), and barriers 
(lamented over needing PrEP as it seems to represent that the relationship is open and he is looking for 
more commitment, sometimes has trouble remembering dose times when family visits). Facilitator is 
not sure about the relationship dynamics the person is reporting and worries that asking about needs 
for higher commitment in the relationship may be too far outside the person’s control. The facilitator 
decides to center a question about needs on consistent dosing when family visits. The facilitator 
believes if the relationship part is more pressing, the person will return to it and bring it up.  
What do you feel would need to happen for you to feel more consistent in taking PrEP when family visits? 
[IDENTIFY NEED TOPIC 2] 
I hear you saying that you would need some access to privacy. How does access to privacy help? [IDENTIFY 
NEED TOPIC 2] 
So privacy is not so much for confidentiality but because you want to have a minute to yourself, away from 
the loud talking and occasional arguing and that is the situation you want for taking your dose. Right? 
[IDENTIFY NEED TOPIC 2] 
How could you see getting a moment to yourself when family visits? [STRATEGIZE TOPIC 2] 
So, “taking a shower” seems to be a time when no one bothers you and you have peace. Would trying to 
use the “taking a shower” idea be something you want to try out? Great. [AGREE TOPIC 2] Quick question 
though- if you try that- how will you know it worked? OK- so it you took every dose the week they are here- 
that would be your “proof”. OK. [CONFIRM plan and explore monitoring and adapting for strategy] 
We have talked about a lot today. To confirm I have it right- you mentioned that you would feel more 
motivated around protecting your health if you felt happier more consistently and going to the gym is a 
way to get there- so you are trying that. And for taking PrEP you are going to try to use the “shower time” 
excuse to get a few minutes away from family and be able to take your time and take your dose. Sound 
right? Great- I can’t wait to check in again when you come back. Thank you!   [Confirm full PLAN and 
CLOSE] 
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ADAPTING NSC and iNSC TO YOUR TOPIC(s) 
 
ADAPT AND CHANGE 
 
Flesh out the NSC or iNSC conversations to your specific health area. Use the workbook and exercises to 
help with that. In role plays, create different scenarios where people are in different stages along a 
continuum (if appropriate) and different spaces and places in terms of where they are at with 
contemplating change.  
 
We have provided the basic approach,  but how it looks and sounds depends on your own style, the 
areas you are discussing and the people you are engaging. That is OK. It should sound unique – it is 
supposed to be genuine and organic. What is discussed and the facilitation style is meant to be flexible.  
 
 
DON’T ADAPT (CHANGE)  
 
The only aspects of NSC and iNSC that are not so flexible are (1) the FLOW (explore needs strategy)  
and (2) the “spirit” of the conversation.  
 
THE FLOW is recommended to always lead with exploration- meaning the person you are working with 
should have the chance to share their vision and experience of things before any action or strategy is 
discussed. The biggest learning point in NSC for many facilitators is NOT jumping in and offering 
suggestions for how to solve what they have decided is the issue. To be person-facing, you need to let 
the person you are working with tell you what is pressing to them. You want to let them think through it 
and come to realize their specific need(s) and strategies. We guide, they solve. That flow of going from 
exploration to needs to strategies to action is very important. 
 
The “SPIRIT” (from Motivational Interviewing) is about the relationship you work to establish with 
people. We want people to fee they have a lot of control in the conversation- that they are the focus and 
their needs are respected. If the exchange feels like the facilitator is doing all the talking, is doing one-
way messaging (you must do this or that, you should try this or that), is filling out some form or sheet, or 
is casting opinions and judgements on the person’s choices or circumstances, when it is NOT NSC. The 
relationship and related dynamics are critical. 
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As with any skill, you have to practice.  
Use the monitoring sheets for practice in Appendix E. The self-assessment tool can be used after role-
plays and after sessions to review the important communication and facilitation skills and parts of NSC 
and iNSC, and to identify areas where you may want to improve.  
 
When possible, record your role-plays or sessions. Listen to the recording with the self-evaluation 
form. Always have something to be working on!  
 
Working with fellow facilitators can be extremely beneficial. It not only gives you great practice 
opportunities, but when practicing NSC or iNSC, having regular meetings to debrief on cases and 
experiences can be rewarding, re-energizing, and skills building.  
 
We HIGHLY recommend forming a team when possible – a group of facilitators 
with a supervisor when possible—that can review each other’s implementation 
of NSC or iNSC and debrief regularly (weekly ideally and monthly at minimum). 
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APPLYING iNSC TO TONSE PAMODZI 
For the Tonse Pamodzi project, we use the iNSC approach. iNSC- integrated Next Step 
Counseling- was developed during the iPrEx open label study as a way to check in with 
people trying to use PrEP. It prioritizes ‘Next Steps’ instead of ideal outcomes (100% 
adherence every day!) to change the conversations from telling people what they must do 
to asking people to share where they really are at with adherence in the context of their 
current resources and limitations. While an ideal outcome might be dosing daily every day, 
a next step might be figuring out how to keep medication on hand when traveling because 
that is what someone says would be helpful. Making PrEP or ART as easy or manageable as 
possible is the goal, but how someone gets there depends on where they are now, what 
matters to them, how they feel about PrEP or ART in the first place, and what their own 
goals are with adherence.  
 
The approach is called ‘integrated’ because that process of exploring where people are at 
and working with them to identify their own needs and next steps is done twice in one 
conversation- once in relation to sexual health and wellbeing in general and once in relation 
to adherence specifically. So, the topics are integrated in their common approach 
(exploration, identifying needs, discussing strategies and agreeing on goals) but happen in 
two different steps because while the two topics are related, the facilitators, barriers, 
needs and strategies for dosing daily can be unique from those that relate to sexual health 
and well-being. 
 
For the Tonse Pamodzi project, iNSC is applied to two groups of women- all of whom are 
expecting at the time of enrollment, but who differ in terms of current HIV status. Some 
women will be living with HIV and starting ART (or restarting after a gap) and others will 
not have HIV but rather will be starting PrEP for prevention of HIV during pregnancy and 
breastfeeding. The content that arises from the discussions with each group will have 
unique features, but the process and flow of iNSC will be consistent between the groups.  
 
Where iNSC notes TOPIC 1 and TOPIC 2, that will be informed by whether the woman is 
starting or restarting ART to treat HIV or the woman is in some phase of consider, using, 
coming off or re-starting PrEP. For Tonse Pamodzi, the EXPLORE part of iNSC where we 
learn about the woman’s specific lived experiences around HIV treatment or prevention is 
critical to guiding the conversation towards person-facing outcomes.  
 
Each woman is different. Her HIV status and reasons she is using ARVs will also be part of 
her unique story. Counselors work with each woman to learn her story and help her on 
what can be a difficult journey. As such, listening skills, reflection, and being present are as 
essential as following the session steps.  
 
Facilitators have already read through the standard workbook with the women in Tonse 
Pamodzi in mind. Over the next section, we add a little more to the background for our 
project, and provide examples for implementing the approach in the diverse situations 
facilitators will encounter.  
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A LITTLE MORE BACKGROUND FOR TONSE PAMODZI FACILITATORS 
Recall the cascade of care for HIV we presented earlier? For Tonse Pamodzi, women living with HIV are 
likely to be around initiation and sustaining on ART in the cascade, but we need to check in with them 
about how they are feeling about it when we EXPLORE with them.  
 
For women who are considering or using PrEP to prevent HIV, they can be anywhere on the continuum 
below. 
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TRY the Mutuality Model! A number of scenarios are offered below. Think about each one. Talk it over 
with a partner. You can’t really know what you would say or do in the real situation, but imagining 
what may happen can help you to prepare.  
 
TRY IT 
YOU ARE EXPLORING WITH SOMEONE WHO IS STARTING PREP…HOW DO YOU LEARN 
ABOUT HER FEELINGS ABOUT IT? HOW DO YOU LEARN ABOUT HER DYNAMIC?  HOW WILL 
UNDERSTANDING HER CURRENT SITUATION INFORM YOUR FACILITATION? 
 
TRY IT 
YOU ARE EXPLORING WITH SOMEONE WHO IS STARTING ART FOR THE FIRST TIME…HOW DO YOU LEARN 
ABOUT HER FEELINGS ABOUT IT? HOW DO YOU LEARN ABOUT HER DYNAMIC?  HOW WILL UNDERSTANDING 
HER CURRENT SITUATION INFORM YOUR FACILITATION? 
 
TRY IT 
YOU ARE EXPLORING WITH SOMEONE WHO IS STARTING ART AFTER BEING ON IT FOR A FEW MONTHS AND 
COMPLETELY STOPPING. HOW DO YOU LEARN ABOUT HER FEELINGS ABOUT IT? HOW DO YOU LEARN ABOUT 
HER DYNAMIC? HOW WILL UNDERSTANDING HER CURRENT SITUATION INFORM YOUR FACILITATION? 
TRY IT 
YOU ARE EXPLORING WITH SOMEONE WHO HAS BEEN PRESCRIBED PREP FOR 1-MONTH. SHE IS BETWEEN 
DISTRUST AND UNCERTAINTY. HOW DO YOU ENGAGE HER IN A CONVERSATION THAT WOULD INVITE HER TO 
SHARE THAT?  HOW WILL THAT INFORM YOUR FACILITATION? 
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CASE SCENARIOS TONSE PAMODZI 
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Primer on communication and facilitation skills 
APPENDIX B 
IMPLEMENTING NSC/iNSC OVER TIME 
APPENDIX C    




Self-monitoring and supervisory tool implementation and fidelity 
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These are NOT Reflections 
 
Ordering, directing or commanding 
Warning, cautioning or threatening 
Giving advice, making suggestions or providing 
solutions 
Persuading with logic, arguing, lecturing 
Telling people what they should do 
Disagreeing, judging, criticizing or blaming 
Agreeing, approving, praising 
Shaming, ridiculing or labeling 
Interpreting or analyzing 
Reassuring, sympathizing, consoling 
Questioning or probing 






Use person’s own words when possible 
Highlight any change talk 
Highlight discrepancies between wants and current behaviors 
Roll with resistance 
Are statements- not questions or commentary 
“You notice that you would like things to be different but feel really confused about how you could 
possibly change right now.” 
 
http://www.michigancancer.org/bcccp/WiseWomanProgram/PDFs/Tutorials/MotivationalInterviewing.pdf 
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DISCRETE COMMUNICATION/FACILITATION SKILLS 
We covered several of these earlier in the workbook. Look over each situation or exchange presented in the table 
below. We include an abbreviation here because these are also things we use in self-monitoing and supervisory 
tools- so have a shorthand to refer to a strategy is helpful when marking up transcripts. The important part is to 
think about the exchange or interaction presented and consider if it is something you do well, do unconsciously, 
want to work on or consider valuable, in all or certain circumstances. Most are not good or bad, they simply are 
strategic ways of communication that facilitators should use with awareness. Mindfullness over what you 
communicate and how is critical to being an excellent facilitator. Go through each description and think about 
how or when you might choose to use or avoid them and when. 
 
TERM Additional context Description 
 
With Permission (ADP) 
Asking before providing 
advice/recommendation 
 Advise (AD) 
Without Permission (ADW) 
Giving advice unsolicited or without 
permission (note: may be appropriate 
depending on context) 
Affirm (AF) 
Appreciation, expressed 
confidence, reinforcement for 
spec beh/thought 
Reinforcing client comments/reflections on 
positive things/insights (note: does not 
include general praise or positive comments) 
Confront (CO) Challenge ideas, confrontation 
Expressing opposing ideas or overt debating 
with client (note: may be appropriate 
depending on context) 
Contingencies (CT) 
Praise, punishment, disapproval, 
moralizing in response to client 
discourse  
Use of praise, disappointment or concern to 
motivate adoption of change resulting in 
direct or implied contingencies for client to 
“earn” counselor respect or positive regard. 
(note: typically inappropriate in most 
situations) 
Emphasize Control  (EC) 
Emphasis on client personal 
control, choice, and responsibility. 
Reflections or comments that reinforce or 
introduce client choice and power in 
discourse or in general 
Evocation (EV) 
Question, reflection or strategy to 
foster alternative 
viewpoints/change talk 
Introducing or steering conversation towards 
alternatives or inconsistencies in views or 
behaviors (note: distinct from confrontation 
by counselor’s use of reflection and questions 
that target change talk) 
Facilitate (FA) 
Verbiage that supports 
exploration or unfolding issue 
more 
Questions, reflections and non-verbals that 
move client towards continued or deeper 
exploration of an issue 
Filler (FI) Chit chat/report building 
Generic conversation- often promoting a 
sense of history between client and 
counselor or commonality or courtesy 
Follow Change Talk (FC) 
Counselor focus/reflection on 
change talk 
Counselor notes and explores client verbiage 
that reflects desire, ability, reasons for 
change, need for change, commitment 
towards change, action or taking steps 
Missed opportunities to explore 
change talk 
Client expressed desire, ability, reasons, 
need, commitment, action or taking steps 
and counselor does not reflect or explore 
Giving Information (GI) 
General information (GI) Provision of general information 
Protocol (intervention) specific 
information (PI) 
Information about sexual risk, risk 
management, adherence, or PrEP (or other 
material related to protocol/study) 
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Closed Question (QUC) 
Questions with answers that resemble 
response options or yes/no 
Open Question (QUO) 
Questions that cannot be answered with a 
simple option or reply- choices for response 
not provided or implied 
Raise Concern (RC) 
With Permission (RCP) 
Asking to share a concern, worry or fear 
typically in relation to what the client just 
shared 
Without Permission (RCW) 
Stating a concern, worry or fear about 
something the client shared without 
asking/permission (note: may be appropriate 




Changing topics or shifting conversation to 
different content intentionally (eg., to close a 
topic, refocus an unproductive discussion, or 
manage conversation length) 
Changed topic unintentionally or 
producing missed opportunity 
(RDU) 
Topic shifts or changes introduced that were 
not intentional-questions that redirect 
conversation from one area to a different one 
for unclear reasons  
Reflect (RE) 
Simple (RES) 
Reflecting back client statements or 
experiences in a way that maintains client’s 
content or level of insight (echo, repeat, 
rephrase, reword) 
Complex (REC) 
Statements that paraphrase to emphasize 
connections, new insights or offer potential 




Offering an alternative and typically more 
functional or empowering way of looking at 
something the client has shared 
Righting (RT) 
Advocating for prevention/health 
rather than joining in ambivalence 
(RT) 
Statements or questions that emphasize 
what the client should think or do that are 
pro-health or pro-self-care.  
Roll with resistance (RR) 
Joining client in reflecting 
on/feeling negatively about pro-
health/pro-self-care options 
Statements, questions, reflections that join 
client’s negative feelings/thoughts about 
adopting/maintaining a health behavior- 
specific avoidance of touting the “should do” 
point of view 
Silence (SI) 
Strategic use of silence (vs filling 
silence or unintentional 
interruption of it) 
Allowing for silence in an appropriate 
manner- productive silences- and using 
silence to learn about client 
       
 
GLOBAL RATINGS 
   Basic Definition 
Acceptance 
 
Counselor demonstrates openness to client and discourse- 




Counselor demonstrated ability to “sit with” difficult content, 
positions client experiences within the context of his/her life 
and genuinely engages with client.  
Spirit 
 
Overall presence of counselor promotes a supportive 
environment. Counselor appears engages in conversation 
and mixes his or her own expressions and affect to create a 
positive productive working alliance with client. 
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Additional facilitation strategies 
All of the developing discrepancy strategies can be used when exploring 
possible challenges, strengths and strategies for change. These can be 
incorporated into iNSC or t-iNSC. These strategies allow for added exploration 
and tailoring of intervention strategies through open discussions. 
 
Asking evoking questions 
These are questions that prompt the client to reflect on where he or she is presently in 
terms of promoting their health may not be where he or she would like to be. These 
evoke thoughts of potential differences between now and what could be. 
What concerns you most about [current behavior]? 
Why change at all? 
When would change be something to consider? At what point? What indicators? 
 
Asking for elaboration or examples … 
when clients focus either on benefits of current behavior or mention possibility for 
change 
 
If someone is stuck talking mostly about why change is not a good thing because there 
are lots of benefits to staying the same, stay with that line of thinking. Ask the client to 
say more about it. Ask for examples of how no-change is better. This is one way of 
“rolling with resistance” that can feel counter intuitive but often leads clients to their 
own discovery of reasons why change may in fact be preferable to remaining the same. 
 
If a client mentions something, anything, about change or adopting a healthier behavior, 
ask the client to say more about it or provide examples. This fosters the client’s own 
realization that change may be possible and preferred. 
 
Guide client towards exploration of extremes 
Sometimes, pushing thoughts or beliefs to extremes can help someone see behaviors 
and attitudes in a different way. In doing so, you want to consider both sides of 
extremes, summarize what you hear, and ask client to reflect on how it all makes sense 
to him or her. Let the client come to his or her own conclusions. 
What would be the very worst of that? What would be the absolute best? 
 
Look back/Look Forward 
This involves asking the client to either (or both) look back to how things were at some 
point prior to now and how he or she would like things to be in the future. 
What is different now from what you did before? How did that change for you? 
If you look ahead a year from now or 5 years from now, what do you see? What would be 
different? 
 
Explore decisional balance 
Decisions to change or stay the same come, in part, from considering the pros and cons 
of adopting a behavior and pros and cons of keeping the old/current behavior. Walk the 
client through a decisional matrix for PrEP non-adherence and adherence. With the 
completed grid, explore client’s reactions and thoughts about what can and cannot be 
changed/addressed. 
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Tell me some good things about NOT taking a dose a day. Tell 
me the bad things about NOT taking a dose a day. 
Tell me some potential benefits about making sure you take PrEP each day. Tell 
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IMPLEMENTING NSC/iNSC OVER TIME 
iNSC over the long haul 
The following are some tips for performing iNSC over time. 
 
 Context. Use the history and context of the counseling relationship as it 
develops. Talk with clients about things you have shared in past 
conversations, including things you know about the client and his or her 
life. This will help build rapport between you and the client. Counselors 
can also establish trust and convey genuine regard through what some 
might call “small talk”. But often it is the small talk that makes the big 
talk feel genuine! In fact, the kind of calm and openness someone has 
when asking about the client’s friend or family or work is the same kind 
of non-judgmental, supportive, open conversation that is the intended to 
characterize the entire tone of iNSC discussions.
 
 Avoiding fatigue. As soon as discussions feel routine or like you are just 
going through the motions to get to the next step, then fatigue has likely 
set in. If you are bored, it is likely that the client is bored too. iNSC 
recommends a rhythm to a conversation, but using your own words and 
changing those up over time is critical to keeping the
conversation from being “stale” or predictable. We want conversations to 
feel natural and genuine. Responsiveness, flexibility, spontaneity, and 
genuineness are all critical to keeping conversations “fresh” over time. 
 
 Avoiding “forced” exploration. When clients share a lot, the counseling 
sessions can feel really energized, with lots of potential for change and 
possibilities. When clients don’t share much in terms of what gets in the 
way, or about what helps, it can feel like you are up against a wall. How 
do you continue the conversation when you don’t have anything to work 
with?
 
There are many reasons clients may not report challenges: they may not 
be aware of their challenges, they may know their challenges but not 
want to share them, they may feel that a behavior (pill taking, condom 
use) is a habit (“just something they do”), or they may have a strategy 
they use that meets their needs “perfectly.” We ask counselors to value 
and trust the process of the discussion. While it may be tempting to try to 
“make” the client “talk” by asking a lot of questions, resist the 
temptation! 
Respect the resistance and do not try to attack it head on. Instead, work with it…join the 
client in discussing the things that help it to feel so “easy”. You may have concerns that 
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the client is painting an overly positive picture, but try to remain open to 
exploring what the client is willing to explore and see what happens. 
 
 Maintenance. This term comes largely from concepts in stages of change, 
where someone who has adopted a behavior for a certain amount of time is 
thought to be in the process of “maintenance.” They are not changing but 
are maintaining. As a process, maintenance often draws from different 
skills sets than adopting a new behavior or trying to change a behavior. 
When working with someone in maintenance on some behavior, 
reinforcement can be helpful, but a focus on efforts rather than outcomes is 
worthwhile here because you don’t want to create a situation where they 
would be fearful of disappointing you if they slip or return to an old 
behavior. The iNSC goals in this case are often to ‘continue doing what 
you have been doing’. Because you don’t know for sure if someone is in 
maintenance, versus wanting to present him or herself in maintenance, it is 
important not to assume that a check-in is not necessary. It is important to 
provide support to those sustaining PrEP use and/or sexual health 
strategies over time.
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APPENDIX C    
PLANNING FOR WHEN ALL IS FINE 
All good! 
EXAMPLE OF iNSC when people are “FINE” (from iPrEx OLE) 
 
Integrated Next-Step Counseling 
Case Scenario: Client Reports no Barriers 
 
Step 3 in Integrated Next Step Counseling (iNSC) involves exploring clients’ experiences with sexual health 
promotion and PrEP-use behaviors. We do this in an open-ended way because we want to learn how people 
integrate these behaviors into their lives and the challenges they may face. It is not uncommon for 
someone to share that they do not have challenges, barriers, or difficulties with a behavior.  
 
Using iNSC does not depend on someone reporting a barrier. 
 
iNSC is a strengths-based approach. The goal of each conversation is to offer clients the opportunity to talk 
about sexual health promotion and PrEP use, and to enhance and support clients’ knowledge, motivation 
and skills. iNSC does not “hunt” or probe for problems to fix. For clients reporting a feeling of confidence 
and/or ease around a behavior, iNSC helps to identify what strategies facilitates that confidence, why it is 
that those strategies work for this person, and asks clients if they feel that they can continue to use these 
strategies over the next several months.  This includes understanding what needs are satisfied by the 
client’s strategies.  
 
We know that some people will say everything is fine and that sexual health promotion and/or PrEP use is 
“easy,” when in fact it is not. This may be because the client is in a hurry or they just are not comfortable 
openly discussing their experiences. That is OK. Continue with the approach.  
 
Some counselors may find it appealing in these situations to probe, assess, challenge or push to try to find 
something to work on…some barrier to address; this is highly unlikely to “open-up” the conversation and 
may actually distance the client. Other counselors may feel drawn to simply reinforcing “achievements” and 
end the discussion quickly; this is not expected to have long-term benefit since clients may report only 
experiences that gain your praise. 
 
The general process of exploration, identification of needs, and agreeing on a strategy are the keystones of 
iNSC discussions. 
 
We ask that counselors continue with the approach regardless of whether or not a client reports any 
barriers. Below is a case scenario of how one may work with a client reporting no barriers while 
implementing iNSC.  
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iNSC when behaviors are reported as well-integrated 
PrEP use conversation example [note that the sexual health promotion discussion has already occurred for this client and 






Counselor (C): You are getting PrEP again today and before we talk about how things have been going with 
the PrEP pills, I want to check-in with you about this choice. Does getting PrEP still feel like something that 
is a good fit for you? Something you want to try to do? 
Client (X): Yeah. For sure. 
 
STEP 3: EXPLORE  
C: How have things been going with daily PrEP?  
X: Really well. It’s pretty easy to do really. I have no complaints. 
C: What are the things that make it feel so easy for you? 
X: You know, it’s just easy. Like a habit now. I just do it. 
C: Can you help me to understand, because I work with a lot of people who struggle with taking a pill every 
day and it would be really helpful if you could share what makes it or made it a habit for you? 
X: I take supplements in the morning. I always have. I take my tablet at the same time. I almost never miss. 
So it’s just something I do now. I don’t even think about it really. I mean, I think about being on PrEP but I 
don’t worry about ‘did I take it’ or ‘this is so hard’. I just do it. You know. 
 
STEP 4: TAILOR 
 
STEP 5: IDENTIFY 
C: So, by taking it with your supplements you found a way to fit the pills into your life rather than trying to 
change your life to fit in taking the pills. Does that sound right? 
X: Yeah. If you fit it into something you already do it’s easier 
C: And that feels like it works for you most of the time. 
X: Yeah. Not all the time but most of it. 
C: Well most of the time sounds like something you feel good about. Yes? 
X: Yeah. That works for me. 
 
STEP 6: STRATEGIZE 
C: OK. Do you see any situations that might come up in the next few months that would make matching-up 
PrEP to taking your supplements difficult or impossible to do? 
X: Hmm. No. I don’t think so. 
C: Any concerns about keeping this something that feels easy you want to talk about? 
X: Not right now. 
 
STEP 7: AGREE ON 
C: You have figured a way to make pill-taking feel more manageable. Are you willing to keep going with this 
for the next few months? 
X: Definitely.  
 
STEP 8: CLOSE/RECORD 
C: Just to let you know, I or one of the other counselors will be checking in with you again each time you 
come in on how things are going with protecting your sexual health and using PrEP. So I’ll be checking in 
on how things went with talking to your partner about using condoms when you do have sex with other 
people (this was the sexual health protection goal selected by this client), the strategy you came up with for 
promoting your sexual health, and also with how you are feeling about PrEP and experiences around using 
it daily. OK? 
X: Yeah. Sounds good. OK. 
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Counselor (C): You are getting PrEP again today and before we talk about how things have been going with 
the PrEP pills, I want to check-in with you about this choice. Does getting PrEP still feel like something that 
is a good fit for you? Something you want to try to do? 
Client (X): Yeah. For sure. 
 
STEP 3: EXPLORE  
C: How have things been going with daily PrEP?  
X: Really well. It’s pretty easy to do really. I have no complaints. 
C: What are the things that make it feel so easy for you? 
X: You know, it’s just easy. Like a habit now. I just do it. 
C: Can you help me to understand, because I work with a lot of people who struggle with taking a pill every 
day and it would be really helpful if you could share what makes it or made it a habit for you? 
X: I take supplements in the morning. Always have. I take my tablet at the same time. I almost never miss. So 
it’s just something I do now. I don’t even think about it really. I mean, I think about being on PrEP but I 
don’t worry about ‘did I take it’ or ‘this is so hard’. I just do it. You know. 
 
STEP 4: TAILOR 
 
STEP 5: IDENTIFY 
C: So, by taking it with your supplements you found a way to fit the pills into your life rather than trying to 
change your life to fit in taking the pills. Does that sound right? 
X: Yeah. If you fit it into something you already do it’s easier 
C: And that feels like it works for you most of the time. 
X: Yeah. Not all the time but most of it 
C: Well most of the time sounds like something you feel good about. Yes? 
X: Yeah. That works for me. 
 
STEP 6: STRATEGIZE 
C: OK. Do you see any situations that might come up in the next few months that would make matching-up 
PrEP to taking your supplements difficult or impossible to do? 
X: Hmm. No. I don’t think so. 
C: Any concerns about keeping this something that feels easy you want to talk about? 
X: Not right now. 
 
STEP 7: AGREE ON 
C: You have figured a way to make pill-taking feel more manageable. Are you willing to keep going with this 
for the next few months? 
P: Definitely.  
 
STEP 8: CLOSE/RECORD 
C: Just to let you know, I or one of the other counselors will be checking in with you again each time you 
come in on how things are going with protecting your sexual health and using PrEP. So I’ll be checking in 
on how things went with talking to your partner about using condoms when you do have sex with other 
people, the strategy you came up with for promoting your sexual health, and also with how you are feeling 
about PrEP and experiences around using it daily. OK? 
X: Yeah. Sounds good. OK. 
At the transition the C checks in on 
choice. We want to emphasize choice at 
each visit. 
C listens and guides, but does not doubt, 
challenge or probe for barriers. Nor does the C 
just praise and close the conversation. Here the 
C encourages exploration of strengths. 
C decides to focus on supporting the continued use of this reported strategy 
C frames how the strategy is satisfying an 
adherence-related need (PrEP use fitting into an 
existing routine). C respects P’s assessment that 
it works “good enough” for him but offers the 
opportunity for P to say he needs more. 
C confirms that this is a strategy that will 
continue to meet this P’s need(s).  
C offers opportunity to explore further and 
respects P’s decision not to. 
P agrees to continue to use this strategy. 
C confirms of all goals agreed upon for the full 
iNSC discussion which includes the goal from 
the sexual health protection part of the 
discussion. 
C reminds P that each visit will involve this 
kind of check-in. 
This example shows how the counselor was able to guide a discussion around experiences, needs and strategies for 
someone who has a strategy they are reporting works most of the time. The counselor sets the stage for continued open 
conversations and also conveys respect for and engagement with this client. 
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Behavioral Strategies for Sexual Health 
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EXAMPLE SEXUAL HEALTH PLAN 
Behavioral Strategies for Sexual Health 
Behavior Need Strategies 
   
Condom use Access to a condom Get condoms at clinic 
  Keep 4 condoms in 
purse 
 Feel more comfortable 
asking partner to 
wear one 
 
   
Discuss importance of 
HIV testing and 
knowing ones status 
with new partners 
Feel more comfortable 
bringing it up 
 
Discuss self-testing 
Discuss attending ANC visits  
Discuss health and wellness of 
partner and baby 
   
   
ART Use 
 
Need Strategies  
   
Remember each day Cell phone alarm  
   
  Pill bottle in bathroom  
Take pill in the 
morning 
 
Swallowing pill Take pill in the morning 
  
Privacy Hide pills in prenatal vitamin bottle   
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Self-monitoring and supervisory tool implementation and fidelity 
SELF ASSESSMENT TOOL (general and fidelity to iNSC) 
   To work on… (goal for building skills)  
SPECIFIC SKILLS 1         2         3         4         5         6         7 






With Permission (ADP) 1         2         3         4         5         6         7 





for spec beh/thought 








disapproval, moralizing in 
response to client 
discourse  
1         2         3         4         5         6         7 
Emphasize Control  (EC) 
 
Emphasis on client 
personal control, choice, 
and responsibility. 
1         2         3         4         5         6         7 
Evocation (EV) 
 
Question, reflection or 
strategy to foster 
alternative 
viewpoints/change talk 
1         2         3         4         5         6         7 
Facilitate (FA) 
 
Verbiage that supports 
exploration or unfolding 
issue more 
1         2         3         4         5         6         7 
Filler (FI) 
 
Chit chat/report building 1         2         3         4         5         6         7 
Follow Change Talk (FC) 
 
Counselor focus/reflection 
on change talk (FC) 1         2         3         4         5         6         7 
Missed opportunities to 
explore change talk (MO) 1         2         3         4         5         6         7 
Giving Information (GI) 
 
General information (GI) 1         2         3         4         5         6         7 
Protocol (intervention) 
specific information (PI) 1         2         3         4         5         6         7 
Question (QU) 
 
Closed Question (QUC) 1         2         3         4         5         6         7 
Open Question (QUO) 1         2         3         4         5         6         7 
Raise Concern (RC) 
 
With Permission (RCP) 1         2         3         4         5         6         7 











1         2         3         4         5         6         7 
Reflect (RE) Simple (RES) 1         2         3         4         5         6         7 
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   To work on… (goal for building skills)  
SPECIFIC SKILLS 1         2         3         4         5         6         7 
   Increase                 No change                  Decrease  









than joining in ambivalence 
(RT) 
1         2         3         4         5         6         7 
Roll with Resistance (RR) 
 
Joining client in reflecting 
on/feeling negatively about 
pro-health/pro-self-care 
options 
1         2         3         4         5         6         7 
Silence (SI) 
 
Strategic use of silence (vs 
filling silence or 
unintentional interruption of 
it) 
1         2         3         4         5         6         7 
Support (SU) 
 
General support for efforts 1         2         3         4         5         6         7 
Other: 
  
1         2         3         4         5         6         7 
Other: 
  
1         2         3         4         5         6         7 
       
       
       
 
GLOBAL RATINGS 
   Low                                                               High 
Acceptance 
 1         2         3         4         5         6         7 
Empathy/Understanding 
 1         2         3         4         5         6         7 
Spirit 
 1         2         3         4         5         6         7 
 
FIDELITY MOTINORING TOOL 
iNSC  REVIEW IMPLEMENTATION OF THESE AND COMMENT 
1. Introduction and Rapport-building. ฀ 
 
2. Review ฀ 
 
SPLIT THE CONVERSATION 
iNSC TOPIC 1  
3. Explore ฀  
(Situation? Words used? Ideas for next 
time?) 
 
  a. Facilitators ฀ 
(Wording for this? Non-judgmental? 
Assist in pushing for deeper 
understanding?) 
 
  c. Challenges ฀ 
(Wording for this? Non-judgmental? 
Assist in pushing for deeper 
understanding?) 
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4. Tailor ฀ 
(What insights/observations did you 
use? What did you under-use?) 
 
5. Needs ฀ 
(What does client need to make 
progress towards a “next-step” 
improvement?)  
 
6. Strategies ฀ 
(How might client address/continue to 
address needs/wants/desires? What 
questions did you ask or not ask?) 
 
7. Agree/Goal setting ฀ 
(Which strategy will client try? How did 
you work with client to get this? 
Collaborative decision making?) 
 
TRANSITION TO TOPIC 2  ฀ 
(How to you switch gears? Smooth?) 
 
iNSC-TOPIC 2  
3. Explore ฀  
(How did you frame this? What is 
current situation? Where is the person 
at? Words used? Ideas for next time?) 
 
  a. Facilitators ฀ 
(Wording for this? Non-judgmental? 
Assist in pushing for deeper 
understanding?) 
 
  c. Challenges ฀ 
(Wording for this? Non-judgmental? 
Assist in pushing for deeper 
understanding?) 
 
4. Tailor ฀ 
(What insights/observations did you 
use to tailor?) 
 
5. Needs ฀ 
(What does client need to make 
progress towards their next step- light 
improvement to their current situation)? 
How did you inquire about this?) 
 
6. Strategies ฀ 
(What questions did you ask for her to 
generate her own strategies?) 
 
7. Agree/Goal setting ฀ 
(Which strategy will client try? 
Collaborative decision making?) 
 
CLOSE. Thank Participant and 
summarize main insights and goals for 
next contact/next visit ฀  
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University of North Carolina at Chapel Hill  
Consent to Participate in a Research Study 
Adult Participants  - Trial 1 English 
 
Consent Form Version Date: 15 June, 2020 
IRB Study # 19-1060 NHSRC #19/05/2334 
Title of Study: UNCPMZ 41901 - An integrated strategy to support antiretroviral therapy and 
pre-exposure prophylaxis adherence for HIV prevention in pregnant and breastfeeding women: a 
pilot study 
Protocol Version 1.3, dated 15 June, 2020  
Malawi Principal Investigator: Dr. Friday Saidi, MD - UNC Project Malawi. US Principal 
Investigator: Dr. Ben Chi, MD, University of North Carolina at Chapel Hill (UNC-CH). 
Zambia Principal Investigator: Dr. Wilbroad Mutale, MBChB, PhD, University of Zambia. 
UNC-Chapel Hill Department: Obstetrics and Gynecology 
Funding Source and/or Sponsor: National Institutes of Health (NIH) 
Study Contact telephone number:  +265 995 403 113 
 
CONCISE SUMMARY  
The purpose of this study is to find the best ways to help support women who are pregnant and 
breastfeeding with HIV treatment and prevention.  To do this, we are testing the use of next-step 
counseling and adherence supporters during pregnancy and breastfeeding to help with 
medication adherence.  Participation in the study is 6 months and includes 4 clinic visits and a 
postpartum visit. There are also other adherence assessments timed with pharmacy visits. 
Individuals could benefit from the study if this strategy helps them take their medication for HIV 
every day. The main risks include breach of confidentiality and embarrassment/discomfort with 
the personal nature of the questions that will be asked during study visits.   
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary. You may 
choose not to participate, or you may withdraw your consent to be in the study, for any reason, 
without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future.   You may not receive any direct benefit from being in the research study. There 
also may be risks to being in research studies. Deciding not to be in the study or leaving the 
study before it is done will not affect your relationship with the researcher, your health care 
provider, or the local clinic. You do not have to be in the research study in order to receive health 
care. 
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Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.  
 
You will be offered a copy of this consent form.  You should ask the researchers named above, 
or staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study? 
Women who become infected with HIV during pregnancy and breastfeeding have a high chance 
of transmitting the infection to their babies. Adherence to HIV medication is needed to prevent 
transmission of HIV, but some patients find it difficult to remember to take their drugs every 
day. In this study, we want to find out whether support for adherence can increase a women’s 
adherence to HIV medications during pregnancy and breastfeeding. The package of services 
includes a special kind of counseling, called integrated next step counseling (iNSC), and training 
of an adherence supporter selected by the participant. 
Are there any reasons you should not be in this study? 
You should not be in this study if you are under 18 years old, or do not plan on staying in this 
area for the next 6 months, or if you have concerns that your partner may harm you. 
 
How many people will take part in this study? 
A total of 100 women will take part in this study. 
 
How long will your part in this study last? 
Participation in the study is for 6 months.  This includes the visit today, 3 additional clinic visits, 
a pharmacy visit each month and a final end of study visit.  In addition, you will be asked to have 
adherence assessments done on a monthly basis, around the time of your pharmacy visits for 
antiretroviral drugs. 
Today’s enrollment visit will take approximately 1 hour.  Clinic visits at months 1, 3 and 6 take 
from 30 minutes to 1 hour, depending on which group of the study you are assigned.  In addition, 
six weeks after your pregnancy ends we will collect information about your delivery.  This visit 
will take about 30 minutes.    
 
What will happen if you take part in the study? 
During the study you will continue to take your medication for HIV as prescribed.  If you decide 
to take part in the study, at today’s visit we will: 
• Ask you questions about yourself, your partners, your home environment, your emotional 
wellbeing, and some of your behaviours. You may choose not to answer any questions 
you do not want to answer 
• Ask questions and review your medical records to collect information about your medical 
history, including your pregnancy history and HIV history 
• Collect urine to check for any kidney problems, including infection 
• Collect approximately 1-2 tablespoons of blood from your arm.  The blood will be tested 
for your HIV viral load, your blood counts (hemoglobin), and a syphilis test (if not 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046032:e046032. 11 2021;BMJ Open, et al. Saidi F
IRB TEMPLATE Version 2.0 - 12/5/2018 - Do not alter this text box 
 
  Tonse Pamodzi 2 Consent Forms English v1.3, 15 June 2020 Page 3 of 22 
already in your medical record). Some blood will be stored for future testing to check for 
HIV resistance. 
• Collect a sample of vaginal fluid.  This will be done by a research nurse who will use a 
soft swab to collect a sample from the vagina.   
• Ask you for your contact information 
Half of the women in this study will receive integrated next step counseling (iNSC) at each clinic 
visit. The counseling sessions are designed to help you identify and solve problems that you face 
around adherence. They also help you to consider your medication adherence and how it relates 
to other health issues. The length of these sessions will depend on the issues you face, but are 
expected to be approximately 30 min. These sessions will be audio-recorded, so we can make 
sure the counseling is performed correctly. These audio-recordings will be identified by your 
study number and not your name.  
Women getting iNSC will also be asked to choose someone to help them remember to take their 
HIV medications every day. For example, this may be a partner, family member, or friend who 
you are willing to tell you are HIV-positive. If you prefer you may choose someone from the 
clinic to help you remember to take your HIV medications every day. This supporter will 
undergo a short training about supporting adherence for antiretroviral therapy. 
The choice about who receives these support activities and who does not will happen at 
random/by chance (like flipping a coin).   Neither you nor the study staff will be able to choose 
which group you are placed in.   
How often will I be seen for this study? 
You will also come to the clinic for visits at 1, 3, and 6 months after the first visit.  Each visit 
will take about 30 minutes to one hour.  At these visits we will:  
• Ask you questions about your pregnancy and your health, and perform a physical exam 
• Ask questions about your well-being and sexual behavior. This will include questions 
about your partner(s) and any social harms (including intimate partner violence) that you 
may have experienced.   
• At the one-month visit you will have a vaginal swab.   
• At the three and six-month visits you will also have blood drawn for an HIV viral load 
test and urine collected to assess kidney function.  
• If you are assigned to the group of study participants that also receives counseling, you 
will meet with the counselor at each visit. You will also be asked questions about the 
services being offered as part of the study. 
In addition, some blood that is collected will be stored for future testing.   The blood sample will 
be labeled with a code so your identity will not be known.  The samples will be stored at UNC 
Project and will not be kept for more than 5 years.  The samples will not be used for any purpose 
outside of this study. 
In addition to the 4 scheduled visits you will visit the pharmacy to get your medication for HIV 
the same way you would if you were not in this study.  These visits will include counting your 
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pills and answering questions about how many days you have taken your medicines in the past 
month.  
After your pregnancy has ended, we will also collect information about the outcome of your 
pregnancy.   
In addition to the above study activities, you may be asked to have a separate interview to talk 
about your experiences in the current study.  You will be asked to sign a separate consent form to 
participate in this part of the study. 
You may also be contacted about future research projects as well. If you are contacted, you will 
receive information about the study and, if you wish to join, you will be asked to sign a separate 
consent form. 
Will I receive test results from the study? 
You will be notified about test results that may help to guide your clinical care. 
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge. The benefits to you include 
taking your HIV medication every day, which will help you to be healthy and prevent HIV 
transmission to your baby and partner(s).  It is also possible that you will not benefit from taking 
part in this study.  
 
What are the possible risks or discomforts involved from being in this study? 
Taking part in this study involves the following risks: 
The collection of blood from your arm may cause some discomfort, light-headedness, bleeding, 
swelling, or bruising where the needle enters the body, and in rare cases, fainting, or infection. 
The staff collecting the blood will be trained and will try hard to minimize these problems.  
You may become embarrassed, anxious or worried when we ask you personal questions about 
your pregnancy, sexual behaviors, or HIV history. You are free not to answer any question that 
you do not want to. The staff involved in the counseling are trained specifically to provide 
integrated next step counseling.  
There is also the risk of breach of confidentiality.  The study staff will take precautions to ensure 
the confidentiality of all study data.  All participants will be assigned a unique study ID number, 
and this number will be used on all study documents and specimens.  Consent forms will be kept 
in a locked cabinet  
There may be uncommon or previously unknown risks. You should report any problems to the 
researcher. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect 
your willingness to continue your participation.  
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How will information about you be protected? 
Every effort will be made to keep your personal information confidential. It will be your decision 
whether you share any information about this study with others in your home or community. We 
will not do so. Your study information will be identified by a code to protect your privacy. Any 
publication about the results will not use your name or identify you personally. 
Your records may be reviewed by representatives of the ethical and regulatory committees in 
Malawi-National Health Sciences Research Committee (NHSRC) and the University of North 
Carolina Institutional Review Board, the study sponsor (NIH), the U.S. Office for Human 
Research Protections, study staff, or study monitors. This is for quality control and safety 
purposes.  
We may use gather data from this project to study other important research questions; however, 
all information will be removed so you cannot be personally identified. 
Any recordings of the counseling sessions will be deleted after they have been transcribed 
(written down), and any identifying information will be deleted.   
What is a Certificate of Confidentiality? 
Most people outside the research team will not see your name on your research information. This 
includes people who try to get your information using a court order in the United States. One 
exception is if you agree that we can give out research information with your name on it or for 
research projects that have been approved under applicable rules. Other exceptions are for 
information that is required to be reported under law, such as information about child or disabled 
abuse or neglect or certain harmful diseases that can be spread from one person to another.  
Personnel of a government agency sponsoring the study may also be provided information about 
your involvement in the research study. 
What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you.  It is unlikely that you 
will be injured as a result of study participation. If you are injured, the UNC Project will give 
you immediate necessary treatment for your injuries. You will not have to pay for this treatment. 
You will be told where you can get additional treatment for your injuries. There is no program to 
pay money or give other forms of compensation for such injuries either through this institution or 
the United States National Institutes of Health. You do not give up any legal rights by signing 
this consent form. 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, for any reason.  The investigators also have the 
right to stop your participation at any time.  
Will you receive anything for being in this study? 
You will be receiving the Malawi Kwacha equivalent of $10 for each study visit you complete.  
This amount is to cover the costs of your transport expenses to and from the clinic.   
 
Will it cost you anything to be in this study? 
It will not cost you anything to be in this study.  
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Who is sponsoring this study? 
This research is funded by the National Institutes of Health (NIH).  This means that the research 
team is being paid by the sponsor for doing the study.  The researchers do not, however, have a 
direct financial interest with the sponsor or in the final results of the study. 
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions about the study (including payments), complaints, concerns, or if a research-
related injury occurs, you should contact the researchers listed on the first page of this form. 
 
A description of this clinical trial will be available on www.clinicaltrials.gov, as required by U.S. 
Law. This website will not include information that can identify you. At most, the website will 
include a summary of the results. You can search this website at any time. 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact, , the Chairman, Dr. Matias 
Joshua 0999397913.  
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SIGNATURE PAGE 
 
IRB # 19-1060 
 
Title of Study: UNCPMZ 41901 - An integrated strategy to support antiretroviral therapy 
and pre-exposure prophylaxis adherence for HIV prevention in pregnant and 
breastfeeding women: a pilot study 
 
 
Principal Investigator: Drs. Ben Chi and Wilbroad Mutale 
 
Participant’s Agreement:  
 
If you have read this informed consent, or have had it read and explained to you, and understand 
the information, and you voluntarily agree to participate in this research study, please sign your 
name or place your thumbprint in the signature area at the bottom of this page. 
 
PART A: LITERATE PARTICIPANT 
 
Participant is literate:   
 
 
______________________________   ____________________________         __________   
Participant Name (print)                                    Participant Signature               Date   
 
 
______________________________               ____________________________ __________     
Study Staff Conducting Consent               Study Staff Signature              Date  
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PART B : ILLITERATE PARTICIPANT 
 
Participant is illiterate:  
 
The study staff  must complete this section, ONLY if an impartial witness is available.  
 














                
Participant Name (print)       Participant Thumbprint       Date 
           
 
Participant Name and Date Written By………………………………………………….on…...……… 
 
  
___________________________________    ______________________________     ___________     
Study Staff Conducting Consent                      Study Staff Signature              Date                  
Discussion (print)           
 
 
___________________________________    ______________________________     ___________   
Impartial Witness Name                        Impartial Witness Signature            Date    








Thumbprint of participant 
if unable to sign 
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University of North Carolina at Chapel Hill 
Consent to Participate in a Research Study 
Adult Participants - Trial 2 English. 
 
Consent Form Version Date: 15 June, 2020 
IRB Study:  UNC# 19-1060; NHSRC #19/05/2334 
Title of Study: UNCPMZ 41901 - An integrated strategy to support antiretroviral therapy and 
pre-exposure prophylaxis adherence for HIV prevention in pregnant and breastfeeding women: a 
pilot study 
Protocol Version 1.3, dated 15 June, 2020 
Malawi Principal Investigator: Dr. Friday Saidi, MD - UNC Project Malawi. US Principal 
Investigator: Dr. Benjamin Chi, MD, University of North Carolina at Chapel Hill (UNC-CH). 
Zambia Principal Investigator: Dr. Wilbroad Mutale, MBChB, PhD, University of Zambia. 
UNC-Chapel Hill Department: Obstetrics and Gynecology 
Funding Source and/or Sponsor: National Institutes of Health (NIH) 
Study Contact telephone number:  +265 995 403 113 
 
CONCISE SUMMARY  
The purpose of this study is to find the best ways to help support women who are pregnant and 
breastfeeding with HIV treatment and prevention.  This part of the study focuses on prevention 
of HIV infection in women who are HIV-negative. All participants must be willing to take the 
combination drug, tenofovir disoproxil fumarate and emtricitabine (TDF-FTC), on a daily basis 
to prevent HIV infection. This is called oral pre-exposure prophylaxis, or PrEP, and is approved 
for use among people at higher risk for getting HIV. In this study, we are testing the use of 
integrated next-step counseling and adherence supporters during pregnancy and breastfeeding to 
help pregnant and breastfeeding women take PrEP.  Participation in the study is 6 months and 
includes 4 clinic visits and a postpartum visit. There are also other adherence assessments timed 
with pharmacy visits. Individuals could benefit from the study if this strategy helps them take 
their medication for HIV prevention. The main risks include breach of confidentiality and 
embarrassment/discomfort with the personal nature of the questions that will be asked during 
study visits.  There are also risks associated with taking TDF-FTC. 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary. 
You may choose not to participate, or you may withdraw your consent to be in the study, for any 
reason, without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046032:e046032. 11 2021;BMJ Open, et al. Saidi F
IRB TEMPLATE Version 2.0 - 12/5/2018 - Do not alter this text box 
 
  Tonse Pamodzi 2 Consent Forms English v1.3, 15 June 2020 Page 10 of 22 
in the future.   You may not receive any direct benefit from being in the research study. There 
also may be risks to being in research studies. Deciding not to be in the study or leaving the 
study before it is done will not affect your relationship with the researcher, your health care 
provider, or the local clinic. You do not have to be in the research study in order to receive health 
care. 
 
Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.  
 
You will be offered a copy of this consent form.  You should ask the researchers named above, 
or staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study? 
Women who become infected with HIV during pregnancy and breastfeeding have a high chance 
of transmitting the infection to their babies.  Certain antiretroviral medicines can be taken by 
HIV-negative pregnant and breastfeeding women to prevent new HIV infections. When taken 
daily, the combination drug TDF-FTC can be used in this way, also known as pre-exposure 
prophylaxis (or PrEP). Adherence to PrEP is needed to prevent HIV, but some patients find it 
difficult to remember to take their drugs every day. In this study, we want to find out whether 
support for adherence can increase a women’s adherence to PrEP during pregnancy and 
breastfeeding. The package of services includes a special kind of counseling, called integrated 
next step counseling (iNSC), and training of an adherence supporter selected by the participant.. 
Are there any reasons you should not be in this study? 
You should not be in this study if you are under 18 years old; are unwilling to take PrEP; have 
been told you have hepatitis B, kidney disease, or osteoporosis; do not plan on staying in this 
area for the next 6 months; or if you have concerns that your partner may harm you. We will also 
perform some blood tests to make sure PrEP is safe for you. 
 
How many people will take part in this study? 
A total of 200 women will take part in this study. 
 
How long will your part in this study last? 
Participation in the study is for 6 months.  This includes the visit today, an enrollment visit, 3 
additional clinic visits, a pharmacy visit each month and a final end of study visit.  In addition, 
you will be asked to have adherence assessments done on a monthly basis, around the time of 
your pharmacy visits for PrEP. 
If you choose to participate, today’s screening visit will take about 1 hour.  The enrollment visit, 
which will take place within 3 weeks and will take approximately 1 hour.  Clinic visits at months 
1, 3 and 6 take from 30 minutes to 1 hour, depending on which group of the study you are 
assigned.  In addition, six weeks after your pregnancy ends we will collect information about 
your delivery.  This visit will take about 30 minutes.    
 
What will happen if you take part in the study? 
At today’s visit we will: 
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• Ask you questions about your medical history 
• Perform a physical exam  
• Collect blood to test for HIV, hepatitis B and kidney function. 
• Ask you for your contact information  
You will be asked to come back to review your lab test results and confirm your eligibility for 
the study. If qualify for the study, you will be formally invited to participate in the study. At this 
enrollment visit, we will again collect blood to test for HIV.  We will also:  
• Ask questions about yourself, your partners, your home environment, your emotional 
wellbeing, and some of your behaviors.  You may choose not to answer any questions 
you do not want to answer 
• Ask questions and review your medical records to collect information about your medical 
history, including your pregnancy history and HIV history 
• Collect urine to check for any kidney problems, including infection 
• Collect approximately 1-2 tablespoons of blood from your arm.  The blood will be tested 
for syphilis (if not already in your medical record) and to make sure your liver is 
functioning normally. 
• Collect a sample of vaginal fluid.  This will be done by a research nurse who will use a 
soft swab to collect a sample from the vagina.   
Half of the women in this study will receive integrated next step counseling (iNSC) at each clinic 
visit. The counseling sessions are designed to help you identify and solve problems that you face 
around adherence. They also help you to consider your adherence in the context of other health 
issues. The length of these sessions will depend on the issues you face, but are expected to be 
approximately 30 min. These sessions will be audio-recorded, so we can make sure the 
counseling is performed correctly. These audio-recordings will be identified by your study 
number and not your name.  
Women getting iNSC will also be asked to choose someone to help them remember to take their 
PrEP medications every day. For example, this may be a partner, family member, or friend who 
you are willing to tell you are taking PrEP. If you prefer you may choose someone from the 
clinic to help you remember to take your HIV medications every day. This supporter will 
undergo a short training about supporting adherence for PrEP. 
The choice about who receives these support activities and who does not will happen at 
random/by chance (like flipping a coin).   Neither you nor the study staff will be able to choose 
which group you are placed in.   
How often will I be seen for this study? 
You will also come to the clinic for visits at 1, 3, and 6 months after enrollment.  Each visit will 
take about 30 minutes to one hour.  At these visits we will:  
• Ask questions about your pregnancy and your health, including possible side effects from 
PrEP medicines, and perform a physical exam 
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• Ask questions about your well-being and sexual behavior. This will include questions 
about your partner(s) and any social harms (including intimate partner violence) that you 
may have experienced.   
• At the one-month visit you will also have a vaginal swab.   
• At the three- and six-month visits you will also have blood drawn to test for HIV and 
check the levels of TDF-FTC (the drugs in PrEP) in your blood.  
• Collect samples to make sure your kidneys are working properly.  This includes blood 
tests at three and six months. Urine tests will be done at one-, three-, and six-month visits. 
•  If you are assigned to the group of study participants that also receives counseling, you 
will meet with the counselor at each visit.  You will also be asked questions about the 
services being offered as part of the study. 
In addition to these four scheduled visits you will visit the study pharmacy to get your PrEP 
medication.  These visits will include counting your pills and answering questions about how 
many days you have taken your medicines in the past month.  
After your pregnancy has ended, we will also collect information about the outcome of your 
pregnancy.   
If you become HIV-positive while in the study, we will perform additional tests to confirm the 
diagnosis. We will stop you from taking PrEP and will collect blood to test for HIV drug 
resistance. You will have your study exit visit and will be referred to your local clinic for HIV 
care and treatment. 
Leftover specimens may also be stored for future testing. The blood sample will be labeled with 
a code so your identity will not be known.  The samples will be stored at UNC Project and will 
not be kept for more than 5 years.  The samples will not be used for any purpose outside of this 
study. In addition to the above study activities, you may be asked to have a separate interview to 
talk about your experiences in the current study.  You will be asked to sign a separate consent 
form to participate in this part of the study. 
You may also be contacted about future research projects as well. If you are contacted, you will 
receive information about the study and, if you wish to join, you will be asked to sign a separate 
consent form. 
Will I receive test results from the study? 
You will be notified about test results that may help to guide your clinical care. 
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge. Participation in this study 
could lower your risk of contracting HIV. By doing this, it may also lower the chances your baby 
may get HIV.  It is also possible that you will not benefit from taking part in this study.  
 
What are the possible risks or discomforts involved from being in this study? 
Taking part in this study involves the following risks: 
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The most common risks and discomforts associated with TDF-FTC are: nausea, headache, 
abdominal pain, and weight decrease. These side effects are uncommon and usually resolved 
within the first month of taking these medicines. The less common risks and discomforts associated 
with TDF-FTC are decreases in bone density and moderately reduced kidney function. Rare but 
possible risks may include severe kidney problems. If this were to occur, we would stop the drug 
and closely monitor closely monitor your kidneys with blood tests. 
 
TDF-FTC is widely regarded as safe during pregnancy. Any medication taken while pregnant will 
come in contact with the baby. The baby will be exposed to the medicines in PrEP, but there are 
no studies that have shown an increased chance of birth defects. Most pregnant women who take 
PrEP in the form of TDF-FTC tolerate it well. 
The collection of blood from your arm may cause some discomfort, light-headedness, bleeding, 
swelling, or bruising where the needle enters the body, and in rare cases, fainting, or infection. 
The staff collecting the blood will be trained and will try hard to minimize these problems.  
You may become embarrassed, anxious or worried when we ask you personal questions about 
your pregnancy, sexual behaviors, or HIV history. You are free not to answer any question that 
you do not want to. The staff involved in the counseling are trained specifically to provide 
integrated next step counseling.  
There is also the risk of breach of confidentiality.  The study staff will take precautions to ensure 
the confidentiality of all study data.  All participants will be assigned a unique study ID number, 
and this number will be used on all study documents and specimens.  Consent forms will be kept 
in a locked cabinet  
There may be uncommon or previously unknown risks. You should report any problems to the 
researcher. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect 
your willingness to continue your participation.  
How will information about you be protected? 
Every effort will be made to keep your personal information confidential. It will be your decision 
whether you share any information about this study with others in your home or community. We 
will not do so. Your study information will be identified by a code to protect your privacy. Any 
publication about the results will not use your name or identify you personally. 
Your records may be reviewed by representatives of the ethical and regulatory committees in 
Malawi-National Health Sciences Research Committee (NHSRC) and the University of North 
Carolina Institutional Review Board, the study sponsor (NIH), the U.S. Office for Human 
Research Protections, study staff, or study monitors. This is for quality control and safety 
purposes.  
We may use gather data from this project to study other important research questions; however, 
all information will be removed so you cannot be personally identified. 
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Any  recordings made  as part  of  our counseling sessions will be deleted after they have been 
transcribed (written down), and any identifying information will be deleted.   
What is a Certificate of Confidentiality? 
Most people outside the research team will not see your name on your research information. This 
includes people who try to get your information using a court order in the United States. One 
exception is if you agree that we can give out research information with your name on it or for 
research projects that have been approved under applicable rules. Other exceptions are for 
information that is required to be reported under law, such as information about child or disabled 
abuse or neglect or certain harmful diseases that can be spread from one person to another.  
Personnel of a government agency sponsoring the study may also be provided information about 
your involvement in the research study. 
What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you.  It is unlikely that you 
will be injured as a result of study participation. If you are injured, the UNC Project will give 
you immediate necessary treatment for your injuries. You will not have to pay for this treatment. 
You will be told where you can get additional treatment for your injuries. There is no program to 
pay money or give other forms of compensation for such injuries either through this institution or 
the United States National Institutes of Health. You do not give up any legal rights by signing 
this consent form. 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, for any reason.  The investigators also have the 
right to stop your participation at any time.  
 
Will you receive anything for being in this study? 
You will be receiving the Malawi Kwacha equivalent of $10 for each study visit you complete.  
This amount is to cover the costs of your transport expenses to and from the clinic.   
 
Will it cost you anything to be in this study? 
It will not cost you anything to be in this study.  
 
Who is sponsoring this study? 
This research is funded by the National Institutes of Health (NIH).  This means that the research 
team is being paid by the sponsor for doing the study.  The researchers do not, however, have a 
direct financial interest with the sponsor or in the final results of the study. 
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions about the study (including payments), complaints, concerns, or if a research-
related injury occurs, you should contact the researchers listed on the first page of this form. 
 
A description of this clinical trial will be available on www.clinicaltrials.gov, as required by U.S. 
Law. This website will not include information that can identify you. At most, the website will 
include a summary of the results. You can search this website at any time. 
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What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact, the Chairman, Dr. Matias 
Joshua 0999397913. 
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SIGNATURE PAGE 
 
IRB # 19-1060 
 
Title of Study: UNCPMZ 41901 - An integrated strategy to support antiretroviral therapy 
and pre-exposure prophylaxis adherence for HIV prevention in pregnant and 
breastfeeding women: a pilot study 
 
 
Principal Investigator: Drs. Ben Chi and Wilbroad Mutale 
 
Participant’s Agreement:  
 
If you have read this informed consent, or have had it read and explained to you, and understand 
the information, and you voluntarily agree to participate in this research study, please sign your 
name or place your thumbprint in the signature area at the bottom of this page. 
 
PART A: LITERATE PARTICIPANT 
 
Participant is literate:   
 
 
______________________________   ____________________________         __________   
Participant Name (print)                                    Participant Signature               Date   
 
 
______________________________               ____________________________ __________     
Study Staff Conducting Consent               Study Staff Signature              Date  

















BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046032:e046032. 11 2021;BMJ Open, et al. Saidi F
IRB TEMPLATE Version 2.0 - 12/5/2018 - Do not alter this text box 
 
  Tonse Pamodzi 2 Consent Forms English v1.3, 15 June 2020 Page 17 of 22 
 
 
PART B : ILLITERATE PARTICIPANT 
 
Participant is illiterate:  
 
The study staff  must complete this section, ONLY if an impartial witness is available.  
 














                
Participant Name (print)       Participant Thumbprint         Date 
           
 
Participant Name and Date Written By………………………………………………….on…...……… 
 
  
___________________________________    ______________________________     ___________     
Study Staff Conducting Consent                      Study Staff Signature              Date                  
Discussion (print)           
 
 
___________________________________    ______________________________     ___________   
Impartial Witness Name                        Impartial Witness Signature            Date    








Thumbprint of participant 
if unable to sign 
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University of North Carolina at Chapel Hill 
Consent to Participate in a Research Study 
Adult Participants – English Qualitative Interviews. 
 
Consent Form Version Date: 15 June, 2020 
IRB Study:  UNC# 19-1060; NHSRC 19/05/2334 
Title of Study: UNCPMZ 41901 - An integrated strategy to support antiretroviral therapy and 
pre-exposure prophylaxis adherence for HIV prevention in pregnant and breastfeeding women: a 
pilot study 
Protocol Version 1.3, dated 15 June, 2020  
Malawi Principal Investigator: Dr. Friday Saidi, MD - UNC Project Malawi. US Principal 
Investigator: Dr. Benjamin Chi, MD, University of North Carolina at Chapel Hill (UNC-CH).  
Zambia Principal Investigator: Dr. Wilbroad Mutale, MBChB, PhD, University of Zambia. 
UNC-Chapel Hill Department: Obstetrics and Gynecology 
Funding Source and/or Sponsor: National Institutes of Health (NIH) 
Study Contact telephone number:  +265 995 403 113 
CONCISE SUMMARY 
The purpose of this study is to find the best ways to help support women who are pregnant and 
breastfeeding with HIV treatment and prevention.  This part of the study involves three in-depth 
interviews to collect more information about women’s opinions of a combination adherence 
support package. This includes integrated next-step counseling and adherence supporter training.  
Each interview is expected to take approximately 1 hour, and will occur at enrollment, 3 and 6 
months after enrollment.  There is no expected benefit to you for participating in this part of the 
study.  The main risk is breach of confidentiality.   
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary. You may 
choose not to participate, or you may withdraw your consent to be in the study, for any reason, 
without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future.   You may not receive any direct benefit from being in the research study. There 
also may be risks to being in research studies. Deciding not to be in the study or leaving the 
study before it is done will not affect your relationship with the researcher, your health care 
provider, or the local clinic.  You do not have to be in the research study to receive health care. 
 
Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.  
 
You will be offered a copy of this consent form.  You should ask the researchers named above, 
or staff members who may assist them, any questions you have about this study at any time. 
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What is the purpose of this study? 
The main purpose of this study is to evaluate how well the strategies used in this study work at 
helping women adhere to HIV treatment and prevention.  By interviewing women who 
participated in the main study, we are hoping to understand how people felt about these different 
services.  You are being asked to be interviewed because you participated in the main study and 
we would like to collect information about your experience. 
Are there any reasons you should not be in this study? 
You should not be in this study if you are under 18 years old, or you do not wish to talk about 
your experience in the study. 
How many people will take part in this study? 
A total of 40 women from the main study will take part in the interviews. 
How long will your part in this study last? 
There are three interviews; each is expected to take approximately 1 hour.   
What will happen if you take part in the study? 
If you consent to participate, you will be interviewed by a member of the study staff.  You will 
be asked to talk about your opinions and experiences with the study intervention, what made it 
difficult and what you found helped.   
The interviews will be conducted in a private room and will be recorded to help us have an 
accurate record of the information you provided.   
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge. There are no expected 
benefits to you from participating in the interviews.  
 
What are the possible risks or discomforts involved from being in this study? 
Participation in clinical research includes the risks of loss of confidentiality and discomfort with 
the personal nature of questions, particularly when discussing HIV infection or sexual behaviors. 
Investigators will make every effort to protect participant privacy and confidentiality.  You may 
choose not to answer questions during the interview if you do not want, and you may end the 
interview at any time.  Data that could identify you will not be collected during the interview. 
There may also be uncommon or previously unknown risks. You should report any problems to 
the researcher. 
 
If you choose not to be in the study, what other treatment options do you have? 
You do not have to be in this research study in order to receive antenatal care.  
How will information about you be protected? 
Every effort will be made to keep your personal information confidential. It will be your decision 
whether you share any information about this study with others in your home or community. We 
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will not do so. Your study information will be identified by a code to protect your privacy. Any 
publication about the results will not use your name or identify you personally. 
Your records may be reviewed by representatives of the ethical and regulatory committees in 
Malawi-National Health Sciences Research Committee (NHSRC) and the University of North 
Carolina Institutional Review Board, the study sponsor (NIH), the U.S. Office for Human 
Research Protections, study staff, or study monitors. This is for quality control and safety 
purposes. 
Audio recordings of the interviews will be deleted after the information has been reviewed.  Any 
information that could identify you will not be used. 
 
What is a Certificate of Confidentiality?  
Most people outside the research team will not see your name on your research information. This 
includes people who try to get your information using a court order in the United States. One 
exception is if you agree that we can give out research information with your name on it or for 
research projects that have been approved under applicable rules. Other exceptions are for 
information that is required to be reported under law, such as information about child or disabled 
abuse or neglect or certain harmful diseases that can be spread from one person to another.  
Personnel of a government agency sponsoring the study may also be provided information about 
your involvement in the research study. 
What if you want to stop before your part in the study is complete? 
There is no penalty if you do not give permission to join the study. You can withdraw from this 
study at any time, without penalty. The investigators also have the right to stop your participation 
at any time. 
Will you receive anything for being in this study? 
If you receive a separate trip to the clinic for this interview, you will receive the equivalent of 10 
USD for transportation costs.  
 
Will it cost you anything to be in this study? 
It will not cost you anything to be in this study.  
 
Who is sponsoring this study? 
This research is funded by the National Institute of Health. This means that the sponsor will pay 
for all of the costs associated with the study. The research team will not gain any financial 
benefit from this study or the results of this study. 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions about the study (including payments), complaints, concerns, or if a research-
related injury occurs, you should contact the investigators listed on the first page of this form. 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
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would like to obtain information or offer input, you may contact, the Chairman, Dr. Matias 




IRB # 19-1060 
 
Title of Study: UNCPMZ 41901 - An integrated strategy to support antiretroviral therapy 
and pre-exposure prophylaxis adherence for HIV prevention in pregnant and 
breastfeeding women: a pilot study 
 
 
Principal Investigator: Drs. Ben Chi and Wilbroad Mutale 
 
Participant’s Agreement:  
 
If you have read this informed consent, or have had it read and explained to you, and understand 
the information, and you voluntarily agree to participate in this research study, please sign your 
name or place your thumbprint in the signature area at the bottom of this page. 
 
PART A: LITERATE PARTICIPANT 
 
Participant is literate:   
 
 
______________________________   ____________________________         __________   
Participant Name (print)                                    Participant Signature               Date   
 
 
______________________________               ____________________________ __________     
Study Staff Conducting Consent               Study Staff Signature              Date  
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PART B : ILLITERATE PARTICIPANT 
 
Participant is illiterate:  
 
The study staff  must complete this section, ONLY if an impartial witness is available.  
 














                
Participant Name (print)       Participant Thumbprint       Date 
           
 
Participant Name and Date Written By………………………………………………….on…...……… 
 
  
___________________________________    ______________________________     ___________     
Study Staff Conducting Consent                      Study Staff Signature              Date                  
Discussion (print)           
 
 
___________________________________    ______________________________     ___________   
Impartial Witness Name                        Impartial Witness Signature            Date    





Thumbprint of participant 
if unable to sign 
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